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Salt forms of the active pharmaceutical ingredient (API) are commonly encountered in the
pharmaceutical industry. About half of marketed pharmaceutical products contain the salt form of
the API. Salt disproportionation, where the salt converts to the free form, is an important concern
for pharmaceutical products containing the salt form of a drug. This is because conversion of the
salt to the free form decreases the solubility and/or alters the reactivity, potentially resulting in a
decrease in product quality. However, many of the factors dictating the tendency of a given salt to
undergo disproportionation remain to be elucidated. In particular, the role of the solid-state
properties and crystal structure of the salt on the disproportionation reaction is unknown. In this
study, by utilizing various model salts of weakly basic compounds, we have shown how
differences in the both solid forms as well as the crystal structure of salt in general can led to
differences in its disproportionation. The results of these studies indicated that the salts structures
involving intermediate water molecules as a bridge between API and counterion are resistant to
disproportionation. Salts having a crystalline arrangement where the salt bridge is shielded or those
forming dual salt bridges are also shown to stable against disproportionation. On the other hand,
amorphous salts which lack long range ordered molecular packing are shown to highly prone to
disproportionation. By understanding the correlation of solid form, crystal structure, and excipient
properties to disproportionation, we can rationally design stable salt formulations.

1

PHARMACEUTICAL SIGNIFICANCE AND
BACKGROUND

1.1

Pharmaceutical Significance

The pharmaceutical industry has achieved great success in discovering new drug candidates by
employing high throughput screening, leading to molecules which possesses better target binding
and have higher efficacy [1]. However, a downside of this approach is the poor aqueous solubility
of many of the newly discovered drug molecule [2]. Nearly 90% of emerging drug candidates are
poorly soluble, falling into Class II or Class IV of the Biopharmaceutical Classification System
(BCS) which categorizes permeability and solubility [2, 3]. Depending on the origin of the poor
solubility, compounds have been termed “brick dust” or “greaseballs”. The former compounds are
very insoluble like crystalline rocks and have high melting points, while, the later compounds are
highly lipophilic and often have low melting point. Making these compounds water soluble, and
hence bioavailable, continues to be one of the biggest challenge faced by pharmaceutical
companies [4]. To improve the solubility of these poorly soluble compounds, many approaches
have been established such as use of cyclodextrins, cosolvents, surfactants, co-crystals,
polymorphs, amorphous forms, salts, and lipid-based systems [5]. Among these techniques, the
use of salts is highly common within the pharmaceutical industry, because they are easy to
manufacture. About 50% of marketed small-molecule medicines are available as the salt form
according to Food and Drug Administration’s (FDA) orange book database [6]. Salt forms are
possible for either weakly acidic or weakly basic drugs. As the majority of drugs are weak bases,
the main focus of investigations into salts has been on weakly basic drugs.
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The major advantage of utilizing salts is the enhancement of aqueous solubility. In addition, they
often have improved solid state properties over the free base form, leading to improved
manufacturability and product stability. However, many studies have shown that when the salt
form of drug is mixed with certain basic excipients, a portion of the salt is converted to the free
base, a phenomenon commonly termed salt disproportionation [7, 8]. This transformation could
be of utmost importance since the partial formation of the free base can lead to a decrease in the
dissolution rate and hence the bioavailability [9]. A recent example where this occurred is the case
of prasugrel HCl, a platelet aggregation inhibitor drug. The partial salt-to-free base conversion of
this drug during product manufacturing had consequences in patients with raised gastric pH, where
a decrease in bioavailability was observed [9]. In addition, liberation of free acid/base can also
cause undesirable stability problems with formulations. Unfortunately, commonly used
pharmaceutical disintegrants and lubricants such as croscarmellose sodium and magnesium
stearate have been shown to generate significant amounts of free base form when combined with
susceptible salts [7]. Therefore, it is of considerable practical importance to understand the
underlying mechanism of salt disproportionation. Liquid chromatography, the most commonly
used analytical technique for pharmaceutical analysis, cannot be used to distinguish between salt
or free base in solid form, since it is a solution state analysis method. However, molecular vibration
techniques such as Raman and FTIR spectroscopy can be used to differentiate between the ionized
(transfer of proton to API) and non-ionized state of the drug in solid systems and thus enable the
detection of salt disproportionation [10].

In the pharmaceutical industry, while developing salt formulations, it is very important to identify
and mitigate the risk of salt disproportionation. Many studies have been undertaken in these areas.
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For example, a strategy of making crystalline solid dispersions has been used to prevent the
occurrence of salt disproportionation, whereby the salt and problematic excipients are physically
isolated [11]. In addition, a modeling approach has been utilized to understand the salt
disproportionation process and implemented to select pharmaceutical salts using a quality by
design approach [12]. It has been established that various physicochemical parameters such as
particle size, relative humidity, microenvironmental pH, the pH of the maximum solubility (pHmax),
counter ion selection, and temperature play a major role in governing the rate and extent of the salt
disproportionation [7, 13]. However, the effect of crystal structure packing on salt
disproportionation has not been studied to date. Specifically, there is no reported study which
compares the rate and extent of salt disproportionation among various solid forms of a given
pharmaceutical salt. Given that different solid-state forms of a given drug are common, this is
clearly an important knowledge gap. In addition, the mechanism by which salt disproportionation
occurs is also not well understood and is likely to be related to solid state structure. By
understanding which solid forms are more prone to salt disproportionation versus those which are
resistant, solid forms with a lower risk of undergoing salt disproportionation reactions can be
selected for development. Another key gap is in the area of understanding the role of water in
disproportionation. It is known that moisture/water can promote the disproportionation [13].
However, it is unknown if water content or water activity is the key determinant of
disproportionation extent. This knowledge is important for proper formulation and packaging
design.

In this study, we will monitor various factor which are responsible for the salt disproportionation
and understand underlying mechanisms. First, we will demonstrate that different solid forms of
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salts such as amorphous, anhydrous, and solvates have varying susceptibility for salt
disproportionation. For this purpose, we will use miconazole mesylate (MM) as a model salt.
Various solid forms of MM will be prepared, and selected forms will be evaluated for their
propensity to undergo salt disproportionation. Second, we will assess the effect of excipient
mobility, water content, water activity, and compression on disproportionation of pioglitazone HCl.
We will prepare salt formulation with excipients with different Tg, water content, and water
activity, and then monitor the rate and extent of salt disproportionation. Finally, we will evaluate
the processes involved in the initiation and progress of salt disproportionation reactions.
Specifically, we will monitor not only the morphological changes on the surface of single crystal
or a crystal film of salt in contact with excipients but also the bulk protonation changes in the
excipient film in contact with the salt.

1.2

Background

1.2.1 Pharmaceutical salts
Utilizing the salt form of an active pharmaceutical ingredient (API) has been shown to increase
the solubility of a poorly soluble API by several orders of magnitudes as compared to the unionized
free base form [3]. In addition, salt formation may also decrease physicochemical instabilities of
the API. For instance, the free form of sertraline base is prone to oxidative degradation resulting
in a potency loss in the final formulation. The formation of the salt decreases the oxidation
tendency by keeping the sertraline in protonated form [14]. Therefore, salt forms are an often
preferred formulation strategy to improve the solubility and stability of the API. However, the
occurrence of salt deliquescence and salt disproportionation are the two major drawbacks that need
to be considered during salt form screening. Deliquescence is the phenomenon where the solid
form is liquefied, forming a saturated solution, upon exposure to a critical RH, termed RH0. [15].
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Salt disproportionation is a phenomenon where the salt is converted to the unionized free base
form [7]. Deliquescence of pharmaceutical salts is less common since it generally occurs at a very
high relative humidity, while salt disproportionation may be more prevalent since it can occur with
formulations containing routinely used pharmaceutical excipients such as magnesium stearate and
croscarmellose sodium at relatively lower humidity and temperature conditions [7].
1.2.2 Salt disproportionation reactions
Salt disproportionation is the conversion of the salt form of an API to its free form. Salt
disproportionation reactions are a type of an acid-base reaction. These reactions can be considered
as the reverse process of salt formation. For instance, during salt formation the free base is reacted
with an acid to form the salt, while, in case of disproportionation, the salt of a weak base, when
comes in contact with a basic microenvironmental pH (as induced by a basic excipient), forms the
free base (Figure 1.1) [13]. It has been previously known that storage of a salt in conditions where
microenvironmental pH is above the pHmax of the salt, it would result in disproportionation [3, 16].
In short, for a disproportionation reaction to occur for the salt of a weak base, proton loss is
required. This is facilitated by hydration of the solid material. Due to the omnipresent nature of
water, a small quantity of water is always present in pharmaceutical powders and this trace amount
of water can act as a medium for proton transfer and salt disproportionation [7]. In theory, if water
is eliminated completely, it could stabilize the salt against disproportionation.

Figure 1.1 A General illustration of disproportionation and salt formation processes [13].
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On one hand, an ionizable API with a lower pKa may gain more benefit by forming a salt in terms
of solubility, on other hand, this compound will be more prone to salt disproportionation relative
to a higher pKa compound [17]. To monitor the progress of the salt disproportionation reaction,
various analytical techniques such as Raman spectroscopy, Fourier transformed infrared
spectroscopy (FTIR), and x-ray powder diffraction (XRPD) have been utilized [18, 19]. Salt
disproportionation is also possible during tablet dissolution and in situ Raman and FTIR can be
utilized to monitor its progress [20]. In general, salt disproportionation reactions can occur in solids,
slurries or solutions.
1.2.2.1 Salt disproportionation in the solid-state
In solid-state salt disproportionation, a salt of a weakly basic drug can act as an acid, reacting with
certain basic excipients (whereby the microenvironmental pH is higher than the pHmax for the salt),
leading to formation of free base and excipient salt. This acid-base reaction can be depicted as
shown in the Figure 1.2.

Figure 1.2 Generalized solid-state salt disproportionation reaction

Pioglitazone HCl, when mixed with various tablet lubricants such as sodium stearate, calcium
stearate, and magnesium stearate, was shown to undergo disproportionation to pioglitazone free
base over time (Figure 1.3A) [10]. The representative solid-state reaction involved in the
interaction of pioglitazone HCl with sodium stearate is depicted in Figure 1.3B. The authors
hypothesized that in the solid-state salt disproportionation reaction, solvation at the surface
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increased mobilization of the reactive species, resulting in a change in the microenvironmental pH,
leading to the salt disproportionation reaction [10].

Figure 1.3 (A) Salt disproportionation kinetics for binary blends of pioglitazone HCl
and various metallic stearates stored at 40 °C and 75 % RH [10]. (B) representative
solid-state salt disproportionation reaction of pioglitazone HCl with sodium stearate.

1.2.2.2 Salt disproportionation in slurries
Salt disproportionation reactions have also been monitored during slurrying processes. For
instance, in one study, the kinetics of salt disproportionation for a developmental pharmaceutical
citrate salt were analyzed in the slurry state as a function of time (Figure 1.4) [21]. The curve fitting
data analysis of the kinetics suggested that the decrease in the salt amount follows a first-order
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decay which is similar to Noyes-Whitney type dissolution. In contrast, the data for free base
formation (crystallization) was best fitted with a sigmoidal curve, indicating a nucleation-andgrowth mechanism. These data suggest that the possible mechanism of salt disproportionation in
slurry is dissolution of the salt followed by nucleation and growth of the free base.

Figure 1.4 Salt disproportionation kinetics for slurry of a developmental
pharmaceutical compound MK-Q [21].

1.2.2.3 Salt disproportionation in solvents (liquid-state)
Salt disproportionation in solution occurs when conversion of the charged species (i.e. the salt) to
the neutral species occurs in solution. When a salt of a weakly basic drug is dissolved completely
in water it produces ionized species of the drug molecules. If this solution is combined with a
solution of strong base, it results in disproportionation and neutralization of the charged drug
molecules. This process generally causes the precipitation of the less soluble free base [22]. For
example, when papaverine HCl is dissolved in water and then combined with NaOH solution,
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precipitation of papaverine free base results [23]. In the fields of inorganic chemistry and materials
science, there are a few literature reports which also describe solvent-induced disproportionation,
where a charged salt species loses its charge and generates free base when dissolved in highly
polar solvents such as DMSO and DMF [24].
1.2.3 Parameters which can affect salt disproportionation
There are many parameters which can affect the kinetics and extent of salt disproportionation
reactions. The factors derive from the properties of the API, excipient, counter ion, and the reaction
products formed.
1.2.3.1 The pH of maximum solubility (pHmax)
The pH of the solution saturated with respect to the salt and free base, also known as pHmax is a
key property which plays a critical role in determining the possibility for salt disproportionation
reactions [17]. The concept of pHmax can be easily understood by taking in consideration the pH
solubility profile as shown in the Figure 1.5.

Figure 1.5 Schematic pH solubility profile for a weakly basic drug with pKa of 5
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When the pH is much lower than the pKa, the dissolved drug is mostly ionized and there exists an
equilibrium between the solution and the solid salt. In this region, the pH solubility profile is given
by equation 1,
𝑆𝑇 = [BH + ]𝑠 + (1 +

𝐾𝑎
)
[𝐻3 𝑂+ ]

(1)

Where [BH+]s is the solubility of the salt form, Ka is the acid dissociation constant, and [H3O+] is
the concentration of hydronium ions which is related to the pH of the system according to equation
2,
[𝐻3 𝑂+ ] = 10−𝑝𝐻

(2)

On the other hand, when the pH is higher than the pKa, the dissolved drug is mostly unionized and
there exists an equilibrium between the solution and the solid free base. In this region, if the
solubility of the crystalline free base is represented as [B]s and the pH solubility profile can be
explained by equation 3,
[𝐻3 𝑂+ ]
𝑆𝑇 = [B]𝑠 + (1 +
)
𝐾𝑎

(3)

The intersection point of equations 1 and 3 can be obtained by combining these equations yielding
pHmax as per equation 4, [3, 16].
p𝐻𝑚𝑎𝑥 = p𝐾𝑎 + log

𝑆0
√𝐾𝑠𝑝

(4)

Where the pKa is related to the acid dissociation constant (Ka) of the protonated drug, S0 is the
intrinsic solubility of the free base, and Ksp is the solubility product for the salt. This equation is
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very useful to evaluate the propensity of disproportionation for a salt, specifically the salt of a
weakly basic drug. When the microenvironment pH is less than the pHmax then the salt form is
more stable and there is an equilibrium between the solution and the solid form of the drug salt
[25]. On the other hand, when the pH of the microenvironment is higher than the pHmax, then the
salt form is less stable and there is an equilibrium between the solution and the solid free base of
the drug [7, 14]. Hence, intrinsic solubility of free base, pKa, and solubility product of salt can
indirectly affect the salt disproportionation because they affect the pHmax.
1.2.3.2 pKa
As two thirds of the drug molecules exist as weak electrolytes, it is vital to understand their ionic
equilibrium. If we consider Brønsted-Lowry acid-base principle, an acid is a compound which is
capable of donating a proton whereas a base accepts a proton. This process of proton transfer can
be expressed by equation
𝐾𝑎

𝐻𝐴 + 𝐻2 𝑂 ↔ 𝐴− + 𝐻3 𝑂+

(5)

The equilibrium constant can be expressed as,
𝐾𝑒𝑞 =

[𝐴− ] [𝐻3 𝑂+ ]
[𝐻𝐴][𝐻2 𝑂]

(6)

The acid dissociation constant Ka can be given by the following equation,
𝐾𝑎 = 𝐾𝑒𝑞 × [𝐻2 𝑂] =

[𝐴− ] [𝐻3 𝑂+ ]
[𝐻𝐴]

(7)

In terms of the Sørensen scale, the Ka can be expressed as pKa,
𝑝𝐾𝑎 = − log 𝐾𝑎

(8)
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According to equation 3, the pKa of a compound is directly proportional to the pHmax. Therefore,
a compound with a low pKa will have lower value of the pHmax and the salt of that compound will
be more prone to disproportionation compared to the compound with relatively high pKa. In
addition, the more the basic the excipient, the greater the difference between the pKa of the salt
and the excipient, and the higher the risk of salt disproportionation.
1.2.3.3 Intrinsic solubility of free base
The intrinsic solubility of the free base (S0) is the equilibrium solubility of the free base measured
at a pH at which it exists as the completely unionized form. Similar to the pKa, S0 is directly
proportional to the pHmax. Therefore, for a weakly basic compound, if the S0 is low, pHmax will be
low, making the salt of that compound more vulnerable to disproportionation.
1.2.3.4 Salt solubility and solubility product of salt
The solubility of a pharmaceutical salt is of utmost importance since it governs both dissolution
and subsequent bioavailability. Salt solubilization involves two steps: (1) breaking of the
intermolecular interaction present in the salt crystal lattice, and (2) forming bonds between the
individual drug molecules and the water molecules. Hence any change in the crystal structure or
water properties can change the solubility. The underlying principle of salt form preparation is to
use a counter ion which can alter the pH of the water (unbuffered solution). For instance, for a
weakly basic drug molecule, acidic counter ions are used to prepare salt, and these impart acidity
to the solution (decrease pH). This lowering of the pH will help improve the aqueous solubility of
the drug. During the solubilization of salt, the equilibrium can be expressed by equation 9,
𝐾

[ 𝐵𝐻 + 𝑋 − ]𝑠 ↔ [ 𝐵𝐻 + ]𝑠 + [𝑋 − ]

(9)

K 𝑠𝑝 = [ 𝐵𝐻 + ]𝑠 [𝑋 − ]

(10)
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Where [BH+X-]s is salt in solid-state (undissolved) in equilibrium with the solution, and [BH+]s an
[X-] are the concentration of the drug molecules and counterion respectively. When the counterion
is present in equimolar concentration with the drug molecule,
[ 𝐵𝐻 + ]𝑠 = [𝑋 − ]

(11)

Therefore, based on the equations 10 and 11 the solubility of the salt can be obtained by,
[ 𝐵𝐻 + ]𝑠 = √K 𝑠𝑝

(12)

According to equation 3, the solubility of the salt (√K 𝑠𝑝 ) is inversely proportional to the pHmax.
Hence, a salt with high solubility will have a lower pHmax. Therefore, very soluble salt forms are
more susceptible to salt disproportionation, especially those with a very poorly soluble free base.
Figure 1.6 summarizes the effect of pKa, and solubility of free base and salt on the pHmax [26].
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Figure 1.6 Schematic pH solubility profile for a weakly basic drug with varying (a)
pKa, (b) intrinsic solubility of base and (c) solubility product of salt and its effect on
pHmax [26].

When there is an excess of the counterion present, the equilibrium presented in equation 9 will
shift to left side according to Le Chatelier’s Principle and the solubility will be affected due to the
common-ion effect [27]. In other words, the excess counterion will decrease the solubility of the
salt. Similar phenomenona have also been observed in many studies, where the solubility of a basic
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drug has been shown to decrease due to presence of the NaCl or HCl [28]. Among the many
different counterions, hydrochloride salts are more popular because of their superior capability to
increase the solubility compared to other counterions. However, hydrochloride salts are more
prone to the common-ion effect in vivo, due to the presence of high amount of chloride ions in the
gastro-intestinal tract [29].
1.2.3.5 Particle size of the powdered salt and excipient
As expected for any solid-state reactions, particle size of the materials also plays a role in
governing the rate and extent of the salt disproportionation reaction. Previous studies evaluating
the effect of particle size on salt disproportionation suggested that as the particle size decreased,
the extent of salt disproportionation increases [13]. The reason behind an increase in salt
disproportionation is likely due to an increase in the surface area of the particle, providing greater
points of contacts between salt and excipients. In addition, the small particles have a higher surface
area to adsorb the moisture, which aids in salt disproportionation reactions [13]. Furthermore, the
effect of particle size was also shown to be dependent on the API used. For instance, in one study,
smaller particles of miconazole and sertraline salts showed double the extent of disproportionation
relative to larger particles, however, smaller particles of benzocaine salt showed more pronounced
differences [13].
1.2.3.6 Relative Humidity and Moisture Sorption
Salt disproportionation involves transfer of proton from one molecule to another, which leads to
change in the ionization state of the molecules. Water is the key medium to facilitate proton
transfer. Previous studies show that a small amount of water is always present on the surface of
salt crystals in the form of film, which is sufficient to mobilize species [30-32]. An increase in the
mobility allows higher reactivity toward other species, leading to an increase in the rate and extent
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of reactions and enhances the chemical instability in solids [33-35]. Therefore, it has been shown
that the higher the relative humidity (RH) in which samples were stored, the higher the rate and
extent of salt disproportionation [13].
1.2.3.7 Temperature
As discussed above, the amount of moisture increases the salt disproportionation, thus it would be
anticipated that an increase in temperature would decrease the moisture content, resulting in less
salt disproportionation. Nevertheless, it has been shown that the salt disproportionation increases
as the temperature of the system increases [13].

This can be easily rationalized based on the

increase in the molecular mobility and relative increase in solubility of the salt versus the free form
at higher temperature leading to a greater amount of salt disproportionation. In addition, the higher
temperature also facilitates higher tendency of nucleation of free base [13].
1.2.3.8 Counter ion
Each counter ion imparts unique properties to the salt form. The most common factor which cause
uniqueness is the difference in the pHmax of salts with different counter ions. For instance, the salts
of sertraline are shown to be stable against oxidative degradation, but when mixed with basic
excipients, they showed variation in degradation due to variability in salt disproportionation [14].
HCl, mesylate and heminitrate salts showed 100% salt disproportionation, while the benzoate salt
showed only partial salt disproportionation. The reason behind the low disproportionation in the
benzoate salt is its high pHmax due to its relatively low solubility [14]. In another study, it was
found that if the counter ion is more volatile it will favor a higher percentage of disproportionation.
For instance, an HCl salt of a developmental pharmaceutical compound was found to be more
prone to salt disproportionation then the HBr salt of same compound, due to the volatile nature of
HCl which leaves the system and drives the salt disproportionation reaction [18].
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1.2.3.9 By-product formation
Physicochemical properties of the by-products of the salt disproportionation reactions can also
play a role in governing the salt disproportionation. For example, pioglitazone HCl salt
disproportionation was monitored in the presence of various tablet lubricants such as sodium
stearate, calcium stearate, and magnesium stearate [10]. Among these, the magnesium stearate
showed the highest amount of salt disproportionation along with faster kinetics. It was found that
when magnesium stearate was used, there was a formation of magnesium chloride as a by-product,
which was highly hygroscopic in nature [10].
1.2.4 Excipient properties
Both excipient solubility and their solid form have been shown to affect API salt
disproportionation. More highly soluble excipients have shown to enhance salt disproportionation
[7]. In addition, amorphous excipients might lead to higher disproportionation due to their ability
to absorb moisture. However, trisodium phosphate dodecahydrate (TSPd) is not an amorphous
material but it has shown to yield a higher microenvironmental pH leading to greater salt
disproportionation [7]. Therefore, the actual occurrence of salt disproportionation is more complex
and involves multiple factors. Further research is necessary to understand more parameters which
might affect salt disproportionation.

1.3

Solid forms of pharmaceutical salts

Similar to any organic molecule, salt also have ability to form various solid forms. Sertraline HCl
(Zoloft) is an example of a system having a variety of salt forms [36]. Based on reports from
various companies, there are about 28 different solid forms of this drug that have been discovered
[36]. In addition, the physicochemical properties of anhydrous, solvate and hydrates forms are
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different. Therefore, it would be of interest to study the effect of various solid forms on rate and
extent of salt disproportionation.

1.4

Research overview

In this chapter, the topic of salt disproportionation was introduced along with description of various
factors that can affect the disproportionation was presented.

Chapter 2 focusses on the impact of solid state form on disproportionation. Specifically,
amorphous, anhydrous, and dihydrate forms of the miconazole mesylate were prepared and
evaluated for their disproportionation tendency with croscarmellose sodium and trisodium
dodecahydrate.

Chapter 3 examines the correlation of the crystal structure of the salt to its disproportionation
tendency. In addition, a correlation was also established between the disproportionation and the
change in the surface texture. AFM was used to determine a change in the surface texture and used
as a screening technique to identify salts which would readily undergo disproportionation.

Chapter 4 investigates the effect of excipient properties such as glass transition temperature, water
content and water activity on the disproportionation of a pharmaceutical salt. Furthermore, the
effect of powder compaction on the rate and extent of disproportionation was also evaluated.
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IMPACT OF SOLID-STATE FORM ON THE
DISPROPORTIONATION OF MICONAZOLE MESYLATE

2.1

Abstract

Approximately 50% of solid oral dosage forms utilize salt forms of the active pharmaceutical
ingredient (API). A major challenge with the salt form is its tendency to disproportionate to
produce the unionized API form, decreasing the solubility and negatively impacting product
stability. However, many of the factors dictating the tendency of a given salt to undergo
disproportionation remain to be elucidated. In particular, the role of the solid-state properties of
the salt on the disproportionation reaction is unknown. Herein, various solid forms of a model salt,
miconazole mesylate (MM), were evaluated for their tendency to undergo disproportionation when
mixed with basic excipients, namely tribasic sodium phosphate dodecahydrate (TSPd) and
croscarmellose sodium (CCS), and exposed to moderate relative humidity storage conditions. It
was observed that the rate and extent of salt disproportionation were significantly different for the
various solid forms of MM. As expected, the amorphous salt was highly susceptible to
disproportionation, while the dihydrate salt form was resistant to conversion under the conditions
tested. In addition, binary excipient blends of amorphous and anhydrous forms exhibited a reduced
extent of disproportionation at a higher relative humidity storage condition. This was due to the
competitive kinetics between disproportionation to the free base and conversion to the dihydrate
salt form. The results of this study provide important insights into the impact of solid-state form
on susceptibility to disproportionation that can be utilized for rationally designing robust
pharmaceutical formulations.
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2.2

Introduction

The pharmaceutical industry has achieved great success in discovering new drug candidates by
employing high throughput screening, leading to molecules which possess better target binding
and have higher efficacy [1, 2]. However, many of these newly discovered drug molecules have
poor aqueous solubility [3]. Nearly 90% of emerging drug candidates are poorly soluble, falling
into Class II or Class IV of the Biopharmaceutical Classification System (BCS) which categorizes
them based on their permeability and solubility [3-5]. Depending on the origin of the poor
solubility, compounds have been termed “brick dust” or “greaseballs” [6]. The former compounds
are very insoluble, crystalline compounds with high melting points, while, the later compounds
are extremely lipophilic and often have lower melting points. Rendering these compounds water
soluble, and hence bioavailable, is one of the biggest challenges for pharmaceutical scientists [7].
To improve solubility, many approaches are employed including the use of cyclodextrins,
cosolvents, surfactants, co-crystals, polymorphs, amorphous forms, salts, and lipid-based systems
[8]. Among these techniques, the use of salts is a common approach for commercial formulations,
due to the ease of manufacture. Approximately 50% of marketed small-molecule medicines are
available as the salt form according to the Food and Drug Administration’s (FDA) orange book
database [9]. Salt forms are possible for either acidic or basic drugs. As the majority of drugs are
weak bases, their salt forms have been the main focus of investigations into salt properties.

The major advantage of utilizing salts is the enhancement of aqueous solubility. In addition, they
often have improved solid-state properties relative to the free base form, leading to enhanced
stability [10, 11]. However, many studies have shown that when the salt form of a weakly basic
drug is mixed with certain basic excipients, the counter ion can dissociate from the salt, a
phenomenon commonly termed disproportionation [12-15]. [16]. Understanding the risk for this
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transformation is of utmost importance since the partial formation of the free base in the drug
product can lead to a decrease in dissolution rate and hence bioavailability [16, 17]. A recent
example where this process occurred is exemplified by prasugrel HCl, a platelet aggregation
inhibitor drug. The partial salt-to-free base conversion of this drug during product manufacturing
had consequences in patients with elevated gastric pH, where a decrease in bioavailability was
observed [17]. In addition, the formation of free acid/base can also cause undesirable stability
problems with formulations. Unfortunately, commonly used pharmaceutical disintegrants and
lubricants such as croscarmellose sodium and magnesium stearate, when combined with salts of
weakly basic drugs, have been shown to generate significant amounts of free base (~10%) form
upon storage (10 days) [12]. Therefore, it is of utmost importance to understand the underlying
mechanism of disproportionation. Liquid chromatography, the most commonly used analytical
technique for pharmaceutical analysis, cannot be used to distinguish between salt or free base in
solid form since it is a solution state analysis method. However, solid-state analytical techniques
such as X-ray powder diffraction as well as Raman and infrared (IR) spectroscopy can be used to
differentiate between the ionized and non-ionized state of the drug in crystalline solid systems and
thus enable detection of disproportionation [18-20].

When developing formulations for a pharmaceutical salt, it is critical to identify and mitigate the
risk of disproportionation and therefore extensive research is ongoing in this field [16]. For
example, a strategy of making crystalline solid dispersions has been used to reduce the occurrence
of disproportionation, whereby the salt and the excipient that is responsible for physical instability
are physically isolated [21]. In addition, a modeling approach was developed for the
disproportionation process and implemented to select pharmaceutical salts using quality by design
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[22]. The pH of the maximum solubility (pHmax) for the salt/neutral form pair is considered an
important parameter for indicating the stability of salt form [12, 23]. For the salt of a weakly basic
drug, if pH is below pHmax then the salt form is stable, while for pH values above pHmax, the free
base is stable [12, 23]. Therefore, in a pharmaceutical formulation, any excipient which leads to a
microenvironmental pH greater then pHmax could encourage disproportionation [16, 23]. In
addition, it has been established that various physicochemical parameters such as particle size,
storage relative humidity (RH), counter ion selection, and temperature play a major role in
governing the rate and extent of the disproportionation [12, 24]. However, the effect of different
solid-state forms of the same salt complex on the physical stability of the salt in the presence of
excipients has not been studied to date. Specifically, there is no reported study which compares
the rate and extent of disproportionation among various solid-state forms of a given pharmaceutical
salt such as amorphous, anhydrous, and hydrated forms. Typically, during early stages of drug
development, a salt could be formulated either as amorphous or crystalline anhydrous material.
Importantly, the use of an amorphous salt form as an API has also been seen in commercial
products such as Crestor®, Viracept®, and Accupril®. In addition, even if the crystalline salt form
is used, during the manufacturing unit operations such as milling and wet granulation, there is a
chance for partial amorphization or other solid-state form conversions. Given that different solidstate forms of a particular salt could have different physical and chemical properties, it is important
to understand which solid forms are more prone to disproportionation versus those which are
resistant. Solid forms that show a lower propensity to undergo disproportionation reactions are
desirable for further drug development.
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The goal of this study was to evaluate the link between different solid-state forms of the same salt
and their disproportionation propensity in the presence of excipients. Miconazole mesylate (MM)
is the salt of a weakly basic drug, and has been noted previously to undergo disproportionation
[24]. Therefore, MM was selected as a model salt as different solid-state forms of MM can be
readily prepared. Specifically, amorphous (AMO), anhydrous (AH), and dihydrate (DH) forms of
MM were prepared and their disproportionation tendency in the presence of basic excipients were
evaluated. The hypothesis under evaluation was that the higher the solubility difference between
a metastable salt form and the free base (relative to the solubility difference between the stable salt
form and free base), the greater the tendency to convert to the free base form of the drug when
mixed with basic excipients. Powder blends of MM with either tribasic sodium phosphate
dodecahydrate (TSPd, a model highly basic excipient) or the commonly used pharmaceutical
excipient, croscarmellose sodium (CCS) were prepared. Raman spectroscopy, in combination
with chemometric modelling of the spectroscopy data, were utilized to monitor
disproportionation/phase transformations between different solid-state forms of MM. Additionally,
the effect of RH on differences in rate and extent of disproportionation among various solid forms
of MM salt was also analyzed.

2.3

Experimental section

2.3.1 Materials
Miconazole (MCZ) was obtained from Alfa Aesar (Haverhill, MA). Methane sulfonic acid (MSA)
was purchased from Acros Organics (Fair Lawn, NJ). Trisodium phosphate dodecahydrate (TSPd)
and croscarmellose sodium (CCS) were obtained from Mallinckrodt (Saint Louis, MO) and FMC
(Philadelphia, PA), respectively. Tetrahydrofuran (THF) was purchased from Macron. Ultrapure
water was obtained using a Millipore ultrapure water system (Billerica, MA). All chemicals were

29
>99% of purity. The molecular structures of miconazole mesylate (MM) and the excipients are
shown in Figure 2.1.

Figure 2.1 Chemical structures of MM, TSPd, and CCS
.

Anhydrous MM was prepared by acid-base reaction. In a glass vial, 5 gm of MCZ free base was
dissolved in 4 ml of THF with a magnetic stirrer (700 rpm) at 25 °C. To the same vial, 795 µl of
MSA (1:1 molar ratio) was added dropwise with continuous stirring (with slight ~2 mole % excess
of MSA). The resultant reaction mixture was stirred continuously at 5 °C until MM crystallized
(~2 hr). The solids were then vacuum filtered and washed with 4 mL of THF, which resulted in
formation of a THF solvate of MM. The obtained crystals were subsequently dried in a desiccator
at 65 °C for 24 hr followed by storage with desiccant at 25 °C. Amorphous MM (AMO) was
prepared by melt quenching. The obtained glassy material was stored in a desiccator. To obtain
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MM dihydrate (DH), AH powder was exposed to 75 % RH and 25 °C for 2 days in order to reach
equilibrium. The resulting powder was collected and stored in an air-tight container.
2.3.2 Methods
2.3.2.1 X-ray Powder Diffraction (XRPD)
Diffraction patterns were recorded using a Rigaku SmartLab (XRD 6000) diﬀractometer (The
Woodlands, TX) using Bragg−Brentano mode using CuKα radiation (λ = 1.5405 Å). Samples (~40
mg) were placed onto a glass sample holder. Diffraction data were recorded at room temperature
between 10° to 40° 2θ with a step size of 0.02°, and a scan time of 8 minutes per sample.
2.3.2.2 Single Crystal X-ray Diffraction (SCXD)
To obtain the single crystals of DH, a vial containing 100 mg of AH were exposed to 95 % RH
and 40 °C until the solid underwent deliquescence. The resultant clear solution of MM was then
used to obtain the crystals of DH by simultaneous cooling and evaporation at 25 °C. A crystal
suitable for single crystal X-ray diffraction was mounted on the Mitegen loops or micromesh. This
sample was then placed on the stage and the data were collected utilizing a Rigaku R-axis curved
image plate diffractometer. The instrument was equipped with a MicroMax002+ high-intensity
copper X-ray source (Cu Kα radiation, λ = 1.54184 Å) along with the confocal optics. The
diffraction data were obtained at -173 °C. Detailed information regarding single crystal data
processing is provided in the supplementary information.
2.3.2.3 Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR)
ATR-FTIR spectra were collected using a Bruker Vertex 70 instrument (Bruker Co., Billerica, MA)
equipped with a Golden Gate attenuated total reflectance (ATR) sampling accessory with a
diamond crystal (Specac Ltd., Orpington, UK), as described previously [25]. OPUS software

31
(Bruker Co., Billerica, MA) was used for data collection and analysis. FTIR spectra were generated
by placing samples in contact with the diamond crystal of the ATR accessory, followed by
accumulating 64 scans between 650 cm−1 and 3950 cm−1 at a resolution of 4 cm−1.
2.3.2.4 Polarized Light Microscopy (PLM)
A few particles of each solid form of MM were placed onto a microscope slide, which was then
mounted onto the stage. The images were obtained by an Eclipse E600 POL microscope in
combination with a DS Fi1 camera (Nikon Corporation, Tokyo, Japan) using cross-polarized light
in transmittance mode. The diameters of 100 particles were then measured manually using Image
J software (Version 1.8, developed by the National Institutes of Health) to obtain the particle size
distribution.
2.3.2.5 Sample Preparation for Disproportionation Study
Each solid form of MM (AMO, AH, and DH) was mixed with model excipients (CCS or TSPd) to
produce binary mixtures at a 50% (w/w) ratio. Prior to blending, AMO and AH powders were
individually stored in desiccators over calcium sulfate (W. A. Hammond Drierite Co. Ltd., Xenia,
OH) for a week at 25 °C, while the DH powder was stored in a tightly closed container to prevent
dehydration. 50 mg of each solid form was geometrically mixed with 50 mg of the excipient using
a spatula. All the samples were prepared in a controlled environment of ~20 % RH. Each binary
mixture was prepared in triplicate. Samples were then stored in open vials and exposed to 33, 43,
or 57 % RH and 25 °C. In addition, reference AMO, AH, and DH powders were stored under
similar conditions. The Raman spectra of all samples were taken periodically to monitor the
progress of disproportionation (conversion to MCZ) or phase transformation (conversion to DH).
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2.3.2.6 Raman Spectroscopy
Raman spectra of the samples were collected using a RamanRxn2 Analyzer (Kaiser Optical
Systems, Inc., Ann Arbor, MI) with a PhAT probe. A 785 nm high power NIR diode laser
(Invictus) was used as the light source. The laser spot size was 6 mm and back scattered radiation
was delivered to the base unit via the fiber bundle of the PhAT probe. The instrument was
calibrated using ASTM standards for the laser excitation wavelength (cyclohexane), spectrograph
wavelength (neon atomic lines), and instrument spectral response (white-light source). To obtain
reproducible results from PhAT Raman measurements, a specially designed sample holder with a
controlled thickness was used. To reduce the offset in the baseline, the CCD detector (Charge
coupled device) was cooled to −40 °C and a dark subtraction was automatically applied to each
spectrum. A laser power of 400 mW was used and 6 scans were accumulated at an exposure time
of 10 s each to obtain the Raman spectra. Grams AI (Thermo, Inc. Waltham, MA) was used for
visually monitoring the data, while, for chemometric analyses, the multivariate analysis software
SIMCA v13 (Umetrics AB, Umeå, Sweden) was used for subsequent data processing.
2.3.2.7 Determination of the weight gain (% w/w)
About 50 mg of AMO powder was weighed before and after exposure to 33, 43, and 57 % RH.
The samples were exposed to these humidity conditions for 5 hours to avoid crystallization to the
DH. All samples were analyzed in triplicate. The weight gain (% w/w) was then obtained by
subtracting the initial weight of the sample from the final weight of the sample after exposure to
various RH conditions.
2.3.2.8 Differential Scanning Calorimetry (DSC) analysis
To obtain the thermal profile of various solid forms of MM, a Q2000 DSC (TA instruments, New
Castle, DE) was used. The instrument was equipped with a refrigerated cooling accessory (RCS)
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(TA instruments, New Castle, DE) purged with nitrogen gas. About 10 mg of sample was sealed
into a Tzero pan with a hermetic Tzero lid (TA instruments, New Castle, DE). The samples were
heated using a heating rate of 10 °C/min. The glass transition temperature (Tg) and the onset of
melting temperature were determined using the TA Analysis software (TA instruments, New
Castle, DE).
2.3.2.9 Determination of solubility
The thermodynamic solubility of the DH was obtained in triplicate, using the slurry method [25].
The excess amount of DH was allowed to slurry in water for 48 hr at 25 °C in a jacketed beaker.
Next, the excess solids were separated utilizing an Optima L-100 XP ultracentrifuge (Beckman
Coulter, Inc., Brea, CA) at 35,000 rpm for 25 min. An Agilent 1290 Infinity Series high
performance liquid chromatography (HPLC) system (Agilent Technologies, Santa Clara, CA) was
then used to determine the concentration in the supernatant. An Inertsil® ODS-3 C18 5 μm, 4.6 ×
100 mm column (GL Sciences Inc., Rolling Hills Estates, CA) was used with a mixture of 0.1%
trifluroacetic acid in water (50%) and acetonitrile (50%) as the mobile phase. A ﬂow rate of 1
mL/min and an injection volume of 10 μL were used. Ultraviolet detection at 220 nm was used to
monitor the elution of the compound. The concentration of each sample was obtained by applying
a calibration curve (R2 value of 0.997). Samples were diluted with mobile phase to obtain
concentration values within the range of the calibration plot.
The kinetic solubilities of various solid forms of MM were also determined visually by adding
small quantities of known amounts of material to a fixed volume of water until dissolution ceased.
2.3.2.10 Determination of Saturated Solution pH
The pH of a saturated solution of CCS, TSPd, and DH was obtained by slurrying excess solid in
water for 2 days (10% w/v slurry). For AMO and DH, the pH was measured at a concentration of
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1000 mg/mL and 125 mg/mL respectively. A pre-calibrated VWR Symphony pH meter equipped
with Symphony pH probe (VWR Scientific, Radnor, PA) was used to measure the pH
potentiometrically.
2.3.2.11 Determination of intrinsic dissolution rate (IDR)
The IDR of various solid forms of MM was determined using a Sirius InForm instrument (Sirius
Analytical, Forest Row, UK). A UV dip probe with 2 mm path length was utilized to monitor the
concentration of MM as a function of time. The experiment was carried out using water as a
medium at 25 °C with a stirring speed of 300 rpm. About 20 mg powder of each solid form of MM
was filled in a die with 3 mm diameter. The disk for IDR was prepared by compressing the power
in a Carver press (Carver Inc., Summit, NJ) at 150 psi for 3 sec. The disk containing the sample
was immersed into the solution and UV spectra were obtained periodically. The amount of MM
release at each time point was calculated using a predetermined calibration curve.
2.3.2.12 Determination of pHmax
The pHmax for various solid forms of MM can be calculated based on the following equation [4,
26].
p𝐻𝑚𝑎𝑥 = p𝐾𝑎 + log

𝑆0
√𝐾𝑠𝑝

(13)

Where, the pKa is related to the acid dissociation constant (Ka) of the protonated drug, S0 is the
intrinsic solubility of the free base, and Ksp is the solubility product for the salt. The previously
reported pKa value of 6.9 for MCZ was used to calculate pHmax [24].
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2.4

RESULTS AND DISCUSSION

2.4.1 Preparation and characterization of various solid forms of MM
To check the solid-state purity of the AH salt form of MM and the free base form of miconazole
(MCZ), X-ray powder diffraction (XRPD) and Fourier transform infrared spectroscopy (FTIR)
were performed. The X-ray diffraction patterns (Figure S1) and FTIR spectra (Figure S2) indicated
that the AH salt is present in the pure form without detectable free base. AH was then used to
prepare various solid forms of MM. The DSC data on AH revealed a sharp endotherm with onset
temperature of ~100 °C. This corresponded to the melting event of the anhydrous salt form of MM.
(Figure S3A). Therefore, for preparing AMO by the melt quench method, a temperature of 115 °C
was used to ensure complete melting of AH. This newly obtained AMO showed a Tg with midpoint
of ~38 °C, indicating successful formation of the amorphous form of MM (Figure S3B). The
XRPD data was in agreement with the DSC data, showing a halo, a characteristic feature for an
amorphous material. The amorphous material was found to be stable when stored under dry
conditions (Figure S4A). However, when AMO was exposed to 57 % RH and 25 °C for 2 days, it
gave an XRPD pattern that was different from that obtained from either the AH or MCZ forms
(Figure S4B). Similarly, when AH was exposed to 75 % RH and 25 °C for 2 days, it also converted
to this unknown form (Figure S4C). The unknown form was suspected to be a hydrated crystal of
MM that formed at high humidity conditions. To identify the exact nature of this crystalline form,
single crystal X-ray diffraction analysis was performed on crystals grown from water as a solvent
system. The hydrated form of MM was identified as a dihydrate (DH) (Figure 2.2) and the
calculated XRPD pattern from the single crystal was consistent with that observed for AMO and
AH following storage at 57% RH and 75 % RH, respectively (Figure S4D).
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Figure 2.2 Crystal structure of DH. The circle indicates the presence of four water molecules
per two molecules of miconazole mesylate.

The particle size distribution analysis of different salt forms indicated that AH and DH have very
similar distributions, while particles of AMO MM are slightly larger (Figure S5 and S6). Previous
studies have indicated that particle size can impact disproportionation [24]. Since the observed
distribution was similar, no special measures were taken for particle size control in this study.
2.4.2 Disproportionation of Different Solid-State Forms
After obtaining the AMO, AH, and DH forms of MM and performing initial characterization, the
next step was to evaluate their rate and extent of disproportionation. To qualitatively observe the
tendency of various solid-state forms of MM to undergo disproportionation, the salt forms were
mixed with TSPd followed by storage at 57 % RH for 2 days and were analyzed by both XRPD
and Raman spectroscopy. The XRPD patterns for the AMO and TSPd blend upon storage showed
peaks corresponding to both MCZ and DH. This indicates that AMO mixed with TSPd
disproportionates to form crystalline MCZ, but also undergoes phase transformation to crystalline
DH (Figure 2.3A). For the AH samples, peaks characteristic of the DH are clearly visible by
XRPD, however MCZ peaks, although present, are of low intensity. Note that these samples were
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also characterized using Raman spectroscopy, which provided orthogonal evidence of MCZ
formation in both AMO and AH samples. In contrast, storage of the DH: TSPd blend did not result
in disproportionation and no evidence of peaks characteristic to MCZ could be observed either by
XRPD or Raman spectroscopy. (Figure 2.3A and B). These results indicate that both AMO and
AH are prone to disproportionation, while the DH appears to be resistant.

In addition to

undergoing partial disproportionation, both AMO and AH also show some conversion to DH.
Having established that both AMO and AH undergo both disproportionation and DH formation,
the next step was to quantitatively determine the kinetics and extent of these phase transformations.
Raman spectroscopy, as the more sensitive technique, was selected for quantitative kinetic studies.

Figure 2.3 Overlay of (A) XRPD patterns and (B) Raman spectra for (a) AMO stored with
TSPd at 25°C 57 % RH for 2 days, (b) AH stored with TSPd at 25°C 57 % RH for 2 days, (c)
DH stored with TSPd at 25°C 57 % RH for 2 days, (d) DH only, and (e) MCZ only. In both
(A) and (B), the dotted (2θ = 11.7° or cm-1 = 1506) and dashed (2θ = 15.3° or cm-1 = 1268)
lines indicate the position of the unique peak for MCZ and DH, respectively.
2.4.3 Chemometric models and calibration curves
Raman spectroscopy has previously been used to quantitatively study disproportionation in powder
blends as well as tablets [27]. In the current study, multiple solid-state forms are present during
disproportionation and/or phase transformation. Therefore, Raman spectroscopy together with a
chemometric model were utilized to quantify the amount of MCZ produced as a result of

38
disproportionation and the amount of DH produced as a result of phase transformation of either
AMO or AH. The calibration curves for systems starting with AMO MM (group 1, AMO-DHMCZ) or AH MM (group 2, AH-DH-MCZ) samples were prepared separately. First, Raman
spectra of the various solid forms and excipients were obtained to identify unique peaks to develop
chemometric models for groups 1 and 2. For group 1, unique peaks at 1421 cm-1, 1268 cm-1, and
1506 cm-1 were found to correspond to AMO, DH, and MCZ respectively (Figure 2.4A), while for
group 2, unique peaks at 854 cm-1, 1268 cm-1, and 1506 cm-1 corresponded to AH, DH, and MCZ
respectively (Figure 2.4B). To generate calibration curves, various samples with different known
molar ratios of AMO-DH-MCZ or AH-DH-MCZ were prepared (Table 2.1).
Table 2.1 Mole % ratio of various group 1 and group 2 samples used to prepare chemometric
calibration curve
Sample ID
AMO-DH-MCZ (Group 1) or
AH-DH-MCZ (Group 2)
0-0-100
100-0-0
0-100-0
50-0-50
0-50-50
50-50-0
16-16-68
68-16-16
16-68-16
33.4-33.4-33.4
10-10-80
80-10-10
10-80-10
20-20-60
60-20-20

Mole %
AMO (Group 1) or
DH
AH (Group 2)
0
0
100
0
0
100
50
0
0
50
50
50
16
16
68
16
16
68
33.4
33.4
10
10
80
10
10
80
20
20
60
20

MCZ
100
0
0
50
50
0
68
16
16
33.4
80
10
10
60
20

For the preparation of calibration curves, each sample was freshly prepared in triplicate and stored
in an air-tight vial prior to Raman measurements. For each spectrum, the baseline was corrected,
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and the second derivative was calculated. For group 1, the ratio of peak intensity at 1421 cm-1,
1268 cm-1, and 1506 cm-1, corresponding to AMO, DH, and MCZ respectively, to that of the 1589
cm-1 peak was determined. For group 2, the ratio of peak intensities at 854 cm-1, 1268 cm-1, and
1506 cm-1, corresponding to AH, DH, and MCZ respectively, to that of the 1589 cm-1 peak
(corresponds to aromatic C=C stretching [28]. and is not impacted by disproportionation or phase
transformation) was determined. Respective calibration curves for groups 1 and 2 were then
established by plotting the intensity ratio as a function of their mole percentage in the mixtures.
This data was then subjected to principal components analysis (PCA). The result of the PCA
analysis for groups 1 and 2 indicated that combination of first principal component (PC1) with the
second principal component (PC2) captures 96.6% and 99.2% spectral variations, respectively. In
addition, for both groups 1 and 2, no outliers were detected in the Hotelling’s T2 ellipse at 95%
confidence regions in the score plot of PC1-PC2 (Figure 2.5C and D). A PLS calibration was then
performed using both PC1 and PC2 for both groups 1 and 2 (Figure 2.4E and F). The values of
R2Y and Q2 were also found to be appropriate for quantifying the amount of disproportionation
and phase transformation [18]. Furthermore, the PLS calibration curves were also cross-validated
(Figure 2.5C) utilizing group samples with a similar mole percent ratio as that of the standards in
triplicate. The reasonable values of root mean square error of estimation (RMSEE) and root mean
squares error of cross validation (RMSECV) for both group 1 and 2 (Table 2.2) indicates that there
is a balance between fitting of the model and its predictive power [18, 29]. The points for
calibration and validation are consistent indicating the robustness of PLS models generated. These
PLS models were then utilized to quantify both disproportionation and phase transformation of
various solid forms of MM.
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Figure 2.4 Raman chemometric model development for group 1 (left panel-A, C, and E) and
group 2 (right panel-B, D, and F) calibration models. (A and B) Raman spectra showing
unique peak of each solid form and excipients used in group 1 and group 2, for (a) MCZ, (b)
AMO (group 1) or AH (group 2), (d) DH, (d) CCS, and (e) TSPd; (C and D) PCA models for
calibration standards; (E and F) Representative PLS models of MCZ mole% calibration
standards showing validation samples (identified by prefix ‘V’) along with the important
statistical parameters.
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Table 2.2 The values of root mean square error of estimation (RMSEE) and root mean square
error of cross validation (RMSECV) for calibration groups 1 and 2.
Group 1
Component

Group 2

RMSEE RMSECV

Component

RMSEE

RMSECV

MCZ Mole %

2.5

2.6

MCZ Mole %

2.7

2.8

AMO Mole %

2.9

3.1

AH Mole %

2.9

3.2

DH Mole %

2.4

2.5

DH Mole %

3.1

3.4

2.4.4 Quantitative disproportionation study
To study the effect of various solid forms of MM on disproportionation rate and extent, binary
mixtures of AMO, AH, and DH with TSPd or CCS in a 1:1 ratio (w/w) were prepared. It is known
from previous studies that higher RH will increase the rate and extent of the disproportionation
reaction [24]. Therefore, to test disproportionation at accelerated storage conditions, samples were
exposed to 57 % RH and 25 °C for 25 days. The samples were analyzed by Raman spectroscopy
and the chemometric models were applied to determine the amount of MCZ produced as a result
of disproportionation and extent of formation of DH as a result of phase transformation. The
observed mole % of MCZ and DH formed with TSPd and CCS are shown as a function of time in
Figure 2.5A and B, respectively.
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Figure 2.5 Disproportionation and phase transformation of various solid forms of MM as a
function of time at 57 % RH and 25 °C with (A) TSPd and (B) CCS.

The data show that at 57 % RH, both AMO and AH underwent disproportionation with TSPd and
CCS. AMO underwent a much higher extent of disproportionation compared to AH. The DH form
was resistant to disproportionation over the period of the study, or the level of disproportionation
was lower than the detection limit (<~3%). The amount of disproportionation for AMO was about
six times higher when mixed with TSPd as compared to CCS. Similarly, the amount of
disproportionation for AH was also higher (~three times) with TSPd as compared to CCS. It is
expected that, in the presence of moisture, the excipient with the higher saturated solution pH will
lead to a higher microenvironment pH in a powder blend [12]. This increase in the
microenvironmental pH is known to affect the rate and extent of disproportionation [12]. To
understand why the TSPd blends showed a higher rate and extent of disproportionation for all
samples, saturated solution pH of TSPd and CCS were analyzed. The result indicated that the TSPd
has a very high saturated solution pH of 12.2 ± 0.1 compared to that of the CCS which was found
to be 5.4 ± 0.2. In addition, the proton accepting (buffering) capacity of the excipients can also
impact their ability to cause API disproportionate.13 The proton accepting capacity of the
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excipients used in this study depends on the amount of Na ions available for exchange with the
proton from the API salt. In case of the CCS, according to the manufacturer, [30]. the Na content
is 6.34 % w/w. Therefore, in 50 mg of CCS there will be 3.2 mg of Na, which corresponds to
0.138 mM of Na. For TSPd, the corresponding amount of Na is 0.914 mM of Na. Consequently,
TSPd has a far greater proton accepting capability as compared to CCS, although both excipients
have sufficient proton accepting capacity to completely convert MM to the free base form. Thus
the higher saturated solution pH and proton accepting capacity are consistent with the observation
that the TSPd blends showed a higher extent of disproportionation.

The chemometric analysis also indicated that the amount of DH in binary mixtures of TSPd with
AMO and AH increases as a function of time. This shows that phase transformation of AMO and
AH to DH occurs during the disproportionation study. Further, due to the resistance of the DH
form to disproportionation, rapid conversion of AMO and AH to the DH at higher humidity
conditions would hinder disproportionation. If this is true, then counterintuitively, the extent of
disproportionation might be higher at a lower RH where DH formation is expected to be slower.
To test this hypothesis, we also monitored disproportionation of AMO, AH, and DH at 43 % RH
and 25 °C with results summarized in Figure 2.6A (with TSPd) and Figure 2.6B (with CCS).
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Figure 2.6 Disproportionation and phase transformation of various solid forms of MM as a
function of time at 43 % RH and 25 °C with (A) TSPd and (B) CCS.

Similar to the results of 57 % RH, the AMO showed a higher extent of disproportionation
with either TSPd or CCS than the AH form. DH did not show any detectable disproportionation
with either TSPd or CCS. The data also showed that, for both the TSPd and CCS, the extent of
disproportionation at 43 % RH is higher than that obtained at 57 % RH. To check if lowering of
the storage RH would further increase the extent of disproportionation, the study was also
performed at 33 % RH and 25 °C (Figure 2.7). Interestingly, the data revealed that the extent of
disproportionation was lower than that observed at 43 % RH, but higher as compared to 57 % RH.
In addition, both AMO and AH showed phase transform to DH, indicating that the critical water
activity for conversion from AH to DH formation is less than 33 % RH. Despite slower DH
formation as compared to 43 % RH, the extent of disproportionation was found to be lower at 33
% RH. This could be due to lower mobility in the system at lower % RH, or simply a consequence
of the lower water availability.
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Figure 2.7 Disproportionation and phase transformation of various solid forms of MM as a
function of time at 33 % RH and 25 °C with (A) TSPd and (B) CCS.

To confirm the crystalline nature of the free form, MCZ, produced as a result of disproportionation
of AMO and AH, XRPD analysis was performed for selected samples. Characteristic reflections
of both MCZ and DH were observed, and no evidence of an intermediate amorphous free base
form was detected (Figure S7A-C). Interestingly, during disproportionation of AMO, the amount
of MCZ present as a function of time was observed to decrease slightly after reaching a maximum
value at all storage conditions. We hypothesize that when AMO undergoes disproportionation,
equilibrium is not initially reached between the stable salt form (DH) and the free base since the
metastable AMO form is still present. However, once all the AMO is lost, partial conversion of
MCZ to DH occurs in order to establish an equilibrium between free base and stable salt form
leading to a plateau. Other factors may also contribute to the observed plateau in the extent of
conversion including (1) formation of a MCZ layer on the salt particles, which acts as a barrier
preventing further proton transfer, (2) accessible excipient groups are fully neutralized by protons
from MM, and (3) all remaining AMO or AH solid state forms have transformed to the nonreactive DH form and hence no more AMO/AH is available for disproportionation.
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Control samples consisted of MM alone, either AMO, AH or DH, stored at 25 °C and 57% RH,
43% RH, or 33% RH. Based on the Raman spectroscopy analyses, AMO, AH, and DH did not
show any disproportionation at any condition up to 25 days. However, both AMO and AH
converted to the DH form (Figure 2.8) which was confirmed by XRPD analysis (Figure S7D). In
addition, the XRPD data also showed that there were no changes in powder pattern for the neat
TSPd stored at different conditions, indicating the stability of the TSPd (Figure S7E). The stability
of the MCZ and DH forms produced during disproportionation or phase transformation,
respectively, were also analyzed. XRPD analysis indicates that MCZ and DH does not show any
further phase transformation when stored at 25 °C and 57% RH (Figure S8). Moreover, the mixture
of MCZ and DH (1:1) when stored at higher humidity condition, does not showed any variation in
their composition (Figure S9). These results suggest that both MCZ and DH products are stable in
either neat form or mixture under the experimental conditions.
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Figure 2.8 Disproportionation and phase transformation of pure solid forms of MM as a
function of time at 25 °C monitored at (A) 57% RH, (B) 43% RH, and (C) 33% RH.

A comparison of the extent of disproportionation and phase transformation i.e. DH formation, after
48 hr of storage at various humidity conditions (Figure 2.9) indicated that the extent of
disproportionation of AMO were much higher than those observed for AH in binary mixtures
containing TSPd or CCS at all storage conditions (Figure 2.9A and B). Similarly, the extent of DH
formation were also higher for AMO as compared to AH for all conditions, except in the binary
mixture of AMO:TSPd, where the extent of DH formation were lower than that of AH:TSPd, for
all storage conditions (Figure 2.9C-E). These results suggest that the AMO form is more prone to
undergo disproportionation and also phase transformation to DH. This result is consistent with
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previous research which indicates that the rate of the reaction, in general, will be faster in
amorphous systems compared to its crystalline phase under a given set of conditions [31].

The effect of relative humidity on extent of DH formation and disproportionation were also
evaluated. The analysis confirms that the extent of disproportionation for all samples (AMO and
AH with TSPd or CCS) were highest at 43 % RH, while they were similar at 57 % RH and 33 %
RH (Figure 2.9A and B). In contrast, extent of DH formation was highest at 57 % RH, and slowest
at 33 % RH (Figure 2.9C-E).

A comparison of the extent of DH formation and disproportionation revealed that the extent of DH
formation for AMO:TSPd are lower than the extent of disproportionation at all storage conditions
(Figure 2.9A and C). In contrast, the extent of DH formation for AH:TSPd, AMO:CCS, and
AH:CCS are higher than their extent of disproportionation (Figure 2.9B and D). This inverse
relation between the extent of DH formation and the disproportionation indicates that there is a
competition between DH formation and disproportionation. This is further exemplified by
considering that the extent of DH formation were highest for the powders with no excipients where
there was no disproportionation, intermediate for samples with CCS, and lowest for samples with
TSPd, where greater disproportionation is occurring. However, TSPd samples undergo
disproportionation at a higher extent than CCS samples, even though CCS is an amorphous
excipient, and therefore might be expected to be more reactive. Clearly, the more basic nature and
higher proton accepting capacity of TSPd outweigh the amorphous nature of CCS. For the specific
case of the AMO:TSPd sample, disproportionation is very fast leading to substantial conversion
to MCZ, consequently there is less residual AMO available for conversion to DH. Switching to

49
CCS results in a slowing of disproportionation and hence more conversion to the DH. The
competition between disproportionation and DH formation provides an explanation for the
observations that the extent of disproportionation was highest at 43 % RH. This is readily explained
by the lower amount of DH formation at 43 % RH compared to 57 % RH (Figure 2.9C and D),
allowing more opportunity for conversion to the free base, rather than forming the
disproportionation-resistant DH. In contrast, Hsieh et. al. shown that the highest disproportionation
of anhydrous MM occurs at 57% RH followed by 43 % RH and 33% RH [24]. To understand the
reason behind the difference in disproportionation behavior for anhydrous MM used in this
manuscript compared to the previous study, effect of varying drying condition on solid form of
anhydrous MM was carried out. XRPD and Raman data indicated that depending on the drying
condition and temperature a different solid form of anhydrous MM were obtained (Figure S10).
As a higher drying temperature (65 °C) was used in this study, a different solid form of anhydrous
MM was obtained, which gave a Raman spectrum which was different from the one reported by
previously by Guerrieri et. al. or Hsieh et. al [12, 24]. Therefore, due to different anhydrous MM
form used in this study, we obtained different results for its disproportion compared to previous
study.
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Figure 2.9 Extent of disproportionation and DH formation from AMO and AH at various %
RH after 48 hr. Extent of MCZ formation for samples with (A) TSPd and (B) CCS. Extent of
DH formation for samples with (C) TSPd and (D) CCS. (E) Extent of DH formation for pure
AMO and AH.

Interestingly, even though the DH formation is lower at 33 % RH than at 43 % RH, the extent of
disproportionation is also decreased. At low % RH, due to a low water content, the molecular
mobility of the amorphous salt is expected to be reduced, hindering the process of
disproportionation. To monitor the effect of water on the mobility, AMO was stored at different
RHs and the weight gain and Tg were measured. The results indicated that, due to the lower water
content at 33 % RH, the Tg of AMO was higher than for the sample stored at 43 % RH, indicating
lower mobility for the former sample (Figure 2.10 and S11). However, the Tg of the salt is low
relative to the storage temperature for all RH storage conditions and therefore mobility is probably
not the limiting factor in dictating the extent of disproportionation. Rather, the lower water content
of the sample at 33% RH is probably responsible for the lower observed extent of
disproportionation.
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Figure 2.10 Tg and weight gain of AMO as a function of relative humidity.
2.4.5 Solubility and pHmax
Disproportionation is a type of acid-base reaction that is assumed to occur between species
mobilized in an adsorbed surface layer of water present on particles. It is well known that solutionstate reactions are typically faster than solid-state reactions and indeed, we observe that
disproportionation is very rapid. If we assume that disproportionation occurs in an adsorbed
surface layer of water, then for a given salt, it would be anticipated that a more soluble solid-state
form would have a higher tendency to convert to the free base. Therefore, we expect to see trends
between the solubility of the solid form and the observed extent of disproportionation. To better
evaluate this hypothesis, the solubility of various solid forms of MM was measured.

Both the thermodynamic and kinetic solubilities of various solid forms of MM were determined
and are presented in Table 2.3. When the DH was slurried in water, no change in solid form was
observed (Figure S12). The thermodynamic solubility of DH was found to be 48 mg/mL. The AH
was found to convert to the DH when slurried in water. To evaluate differences in the solubility of
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the different forms, kinetic solubility measurements were also performed. In line with expectations,
AMO has the highest apparent solubility, while the DH form has the lowest solubility. The
apparent solubility of AMO is about an order of magnitude higher than that of AH, while the
thermodynamic solubility of DH is about half of the apparent solubility of AH. Intrinsic dissolution
rate (IDR) measurements were also performed to confirm trends seen with the kinetic solubility
measurements. The data indicated that AMO had the highest IDR of 15 µg/s/cm2, followed by AH
and DH which have IDR of 3 µg/s/cm2 and 2 µg/s/cm2, respectively (Figure 2.11A). These trends
in IDR follow the same order as for the kinetic solubility experiments.

The results of the solubility study are consistent with the disproportionation data which showed
that AMO form has the highest amount of disproportionation, followed by AH, while the DH was
found to be resistant disproportionation. Based on the kinetics solubility values obtained, the
values of pHmax were calculated using equation 2. Results are shown in Table 2.3, and a schematic
pH solubility profile for each solid-state form is shown in Figure 11B. Because of the different
apparent solubility values, each solid-state form yields a different apparent pHmax. AMO has the
lowest apparent pHmax followed by AH and DH. It is known that the lower the value of pHmax, the
greater the driving force for disproportionation. Thus, the difference in the kinetic solubility values
of the different solid-state forms helps explain why AMO undergoes a greater extent of
disproportionation than AH, and why AH in turn shows an increased tendency to convert to the
free base relative to DH.
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Table 2.3 Thermodynamic and kinetic solubilities of various solid forms of MM.

Solid Form

Thermodynamic

Kinetic solubility

Calculated*

Solid form

of MM

solubility mg/mL

mg/mL

pHmax

after 48 hr

AMO

-

1125 ± 25

0.7 ± 0.1a

Dihydrate

AH

-

115 ± 10

1.6 ± 0.1a

Dihydrate

DH

48 ± 1

50 ± 2

2.0 ± 0.1

Dihydrate

*Calculated utilizing the pKa = 6.9 and Solubility of free base = 9.98E-04 mg/mL [32].
aThese values are apparent pH
max values as they were calculated from kinetic solubility data.

Figure 2.11 (A) Intrinsic dissolution rate (IDR) for various solid forms of MM measured at
25 °C and (B) Schematic pH solubility profile indicating pHmax of various solid forms along
with pKa of MCZ and saturated solution pH of excipients.

However, the lack of detectable disproportionation of DH cannot be explained based on
consideration of pHmax values. Thus, even though the pHmax of the DH was found to be 2.0, which
is very low compared to the saturated pH of both TSPd and CSS, the DH form did not show any
disproportionation. There could be multiple reasons behind this phenomenon. It is possible that
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solvation of surface DH molecules followed by disproportionation results in a layer of free base
on the outer surface of DH particles that can prevent further reaction whereby this low extent of
disproportionation is undetected. Alternatively, if the DH is not a salt, then also it might not
disproportionate. However, the crystal structure clearly indicates the hydrogen from the MSA is
transferred to the nitrogen of the MCZ molecule (Figure 2.12), confirming that DH is indeed a salt.
A detailed analysis of crystal structure of DH reveals that the MCZ molecule does not directly
form a salt bridge with the mesylate ion (Figure 2.12). The MCZ molecule forms a hydrogen bond
with a water molecule, which forms a second hydrogen bond with another water molecule and this
water molecule then forms a hydrogen bond with mesylate ion. Consequently, the MCZ molecule
is connected to MSA by intermediate water molecules. Due to this unique and stable crystal lattice
arrangement, it is possible that proton transfer is limited by structural features, preventing
disproportionation from occurring to a detectable amount. Clearly the role of crystal structure in
disproportionation reactions needs to be further investigated given this interesting observation
around DH resistance to conversion.

Figure 2.12 Hydrogen bonding pattern in DH form of MM. Hydrogen bonds of interest are
represented by a dotted blue line along with their respective bond distances.
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2.5

Conclusions

Using miconazole mesylate as a model pharmaceutical salt, we have demonstrated that different
solid forms have varying susceptibilities to disproportionation when mixed with basic excipients
and stored at moderate relative humidity conditions. Importantly, the amorphous salt was found to
show a higher amount of disproportionation than crystalline salts. Interestingly, the crystalline
anhydrate salt underwent conversion to the free base, albeit to a lower extent than the amorphous
form, whereas the crystalline dihydrate salt did not show any detectable disproportionation. This
observation cannot be explained based on pHmax differences between the anhydrate and dihydrate,
since solubility differences were relatively minor. It is thought that the structure of the dihydrate
renders this solid-state form less susceptible to disproportionation. In addition to partial
disproportionation, both the amorphous and anhydrate salts also converted into the dihydrate salt
crystal. The competition between dihydrate formation and disproportionation led to a non-intuitive
relationship between the extent of free base formation and storage relative humidity. This work
highlights the need to consider the impact of salt solid-state form when considering salt stability
to conversion to the free base form. During manufacturing, any processing operations that create
amorphous content in a nominally crystalline salt, e.g. surface disordering, render the salt more
susceptible to disproportionation in the presence of basic excipients. Furthermore, amorphous salts
need to be evaluated not only for crystallization tendency, but also for susceptibility to conversion
to the free form. By understanding role of the various solid forms and excipient properties, together
with a mechanistic understanding of disproportionation, rationally designed and robust
formulations of pharmaceutical salts can be produced.
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2.7

Supporting information

2.7.1 Supporting methods
2.7.1.1 Single crystal X-ray diffraction
Single crystal X-ray measurements were conducted on a Rigaku Rapid II curved image plate
diffractometer with a Cu-K X-ray microsource ( = 1.54178 Å) with a laterally graded multilayer
(Goebel) mirror for monochromatization. Single crystals were mounted on Mitegen microloop
mounts using a trace of mineral oil and cooled in-situ to 100(2) K for data collection. Data were
collected using the dtrek option of CrystalClear-SM Expert 2.1 b32 [1]. Data were processed using
HKL3000 [2] and data were corrected for absorption and scaled using Scalepack [2]. The space
group was assigned and the structures were solved by direct methods using XPREP within the
SHELXTL suite of programs [3] and refined by full matrix least squares against F2 with all
reflections using Shelxl2014 [4] with the graphical interface Shelxle [5]. The crystal under
investigation was found to be non-merohedrically twinned. HKL3000 lacks the ability to
simultaneously integrate more than one twin domain. Rigaku programs compatible with the
diffractometer (twinsolve) gave unsatisfactory results. The data were thus instead handled as if not
twinned, with only the major domain integrated, and converted into an hklf 5 type format hkl file
after integration using the "Make HKLF5 File" routine as implemented in the program WinGX [6].
The twin law and matrix were obtained using the program ROTAX as implemented in WinGX.
The twin operation was identified as a 180 rotation around the reciprocal a-axis, the twin matrix
as 1 0 1.313, 0 -1 0, 0 0 -1. The Overlap R1 and R2 values in the "Make HKLF5 File" routine used
were 0.23, i.e. reflections with a discriminator function less or equal to overlap radius of 0.23 were
counted overlapped, all others as single. The discriminator function used was the "delta function
on index non-integrality". No reflections were omitted.

61
The structure was solved using direct methods with all reflections of component 1. The structure
was refined using the hklf 5 routine with all reflections of component 1 (including the overlapping
ones) as obtained from WinGX, resulting in a BASF value of 0.297(3). No Rint value is obtainable
for the hklf 5 type file using the WinGX routine.

H atoms attached to carbon and nitrogen atoms were positioned geometrically and constrained to
ride on their parent atoms, with carbon hydrogen bond distances of 0.95 Å for aromatic and alkene
H atoms, 0.99 Å for CH2, 0.88 Å for NH, and 0.98 Å for CH3 moieties, respectively. Methyl H
atoms were allowed to rotate but not to tip to best fit the experimental electron density. Water H
atoms were freely refined with O-H bond distances restrained to 0.84(2) Å. Uiso(H) values were
set to a multiple of Ueq(C/N/O) with 1.5 for OH and CH3, and 1.2 for N-H, C-H and CH2 units,
respectively.
Table S1. Experimental details
MICONZ04 (MM dihydrate)
Crystal data
Chemical formula

C18H15Cl4N2O·CH3O3S·2(H2O)

Moiety formula

C18H15Cl4N2O, CH3O3S, 2 H2O

Mr

548.24

Crystal system, space group

Monoclinic, C2/c

Temperature (K)

100

a, b, c (Å)

38.449 (3), 9.0878 (5), 13.6903 (9)

 (°)

103.528 (5)
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V (Å3)

4650.9 (5)

Z

8

F(000)

2256

Dx (Mg m-3)

1.566

Radiation type

Cu K

No. of reflections for cell measurement

39176

 range (°) for cell measurement

4.7–73.5

 (mm-1)

5.82

Crystal shape

Plate

Colour

Colourless

Crystal size (mm)

0.12 × 0.06 × 0.02

Data collection
Diffractometer

Rigaku Rapid II curved image plate diffractometer

Radiation source

microfocus X-ray tube

Monochromator

Laterally graded multilayer (Goebel) mirror

Scan method

 scans

Absorption correction

Multi-scan, SCALEPACK (Otwinowski & Minor, 1997)

Tmin, Tmax

0.465, 0.893

No. of measured, independent and

39176, 39176, 33902

observed [I > 2(I)] reflections
Rint

n/a
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 values (°)

max = 72.4, min = 4.7

(sin /)max (Å-1)

0.618

Range of h, k, l

h = -4747, k = -1111, l = -1616

Refinement
Refinement on

F2

R[F2 > 2(F2)], wR(F2), S

0.070, 0.205, 1.05

No. of reflections

39176

No. of parameters

303

No. of restraints

4

H-atom treatment

H atoms treated by a mixture of independent and
constrained refinement

Weighting scheme

w = 1/[2(Fo2) + (0.0633P)2 + 49.6689P]
where P = (Fo2 + 2Fc2)/3

(/)max

0.001

max, min (e Å-3)

0.85, -0.82
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2.7.2 Supporting figures

Figure S1. XRPD pattern of (A) MCZ and (B) AH.

Figure S2. FTIR spectrum of (a) MCZ and (b) AH. The dotted vertical lines at 1509 cm-1 and
1036 cm-1 represents unique peaks of MCZ and AH, respectively.
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Figure S3. DSC traces of (A) AH and (B) AMO.

Figure S4. XRPD pattern of (a) AMO stored in a desiccated container for 4 weeks at 25 °C, (b)
AMO stored in 57 % RH for 2 days at 25 °C (c) AH stored in 75 % RH for 2 days at 25 °C, and
(d) calculated XRPD pattern from DH single crystal structure.
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Figure S5. Polarized light microscopic images of (A) AMO, (B) AH, and (C) DH.

Figure S6. Particle size distribution for (A) AMO, (B) AH, and (C) DH.
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Figure S7. XRPD patterns for various sample after storage for 2 days at (A) at 57 % RH, (B) at
43 % RH, and (C) at 33 % RH for (a) AMO + TSPd, (b) AMO + CCS, (c) AH + TSPd, (d) AH +
CCS, (e) DH + TSPd, and (f) DH + CCS; (D) control samples of (a) neat AMO at 57 % RH, (b)
neat AH at 57 % RH, (c) neat AMO at 43 % RH, (d) neat AH at 43 % RH, (e), neat AMO at
33 % RH, and (f) neat AH at 33 % RH. (E) Samples for TSPd stability analysis (a) neat TSPd at
33 % RH, (b) neat TSPd at 43 % RH, (c) neat TSPd at 57 % RH, and (d) neat TSPd before
storage. The dotted and dashed lines indicate the position of unique peak for MCZ and DH,
respectively.
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Figure S8. XRPD pattern of (a) neat DH, (b) neat DH after exposure to 57 % RH for 7 days, (C)

neat MCZ, and (d) neat MCZ after exposure to 57 % RH for 7 days.

Figure S9. Raman spectra of (a) neat DH, (b) neat DH after exposure to 57 % RH for 7 days, (C)
neat MCZ, (d) neat MCZ after exposure to 57 % RH for 7 days, (e) DH + MCZ (1:1) mixture,
and (f) DH + MCZ (1:1) mixture after exposure to 57 % RH for 7 days. The composition of the
mixture of the DH (50 mole %) and MCZ (50 mole %) did not change upon storage at 57 % RH
for 7 days.
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Figure S10. (A) XRPD and (B) Raman spectra of various solid form of anhydrous MM obtained
by different processing and temperature. (a) desolvation of THF solvate at 65 °C, (b) dehydration
of DH at 65 °C, (c) dehydration of DH over P2O5, (d) dehydration of DH at 85 °C, and (e)
dehydration of DH over P2O5 followed by storage at 85 °C. (C) XRPD and (D) Raman spectra of
reference THF solvate before desolvation.

Figure S11. DSC traces of AMO stored at 33 % RH, 43 % RH, and 57 % RH.
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Figure S12. XRPD pattern of solid residues obtained after slurrying DH in water for 2 days.
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ASSESSING THE RISK OF SALT
DISPROPORTIONATION USING CRYSTAL STRUCTURE AND
SURFACE TOPOGRAPHY ANALYSIS

3.1

Abstract

Salt disproportionation is a major hurdle for pharmaceutical products containing a salt form of a
weak base, as conversion of salt to free base during processing or storages decreases the solubility.
A variety of factors affecting the tendency of a salt to disproportionate have been evaluated to date.
However, there are still many factors which remain to be elucidated. Specifically, the role of the
salt crystal structure on the disproportionation reaction is not well understood. Herein, by utilizing
model compounds with similar pKa and pHmax values, we have shown how differences in the
crystal structure can led to differences in its disproportionation. The result of the study indicated
that the salts which lack a direct salt bridge between API and counter ion, and are connected
through intermediate water molecules, show resistance to disproportionation. Salts with molecular
packing where the salt bridge is shielded or where the salt bridge involves more than one
interaction, were also found to be stable against disproportionation. In addition, a correlation was
also established between the event of disproportionation and change in the surface texture of the
salt. The results of this study indicate that in addition to pHmax as a critical parameter to determine
the stability of the salt, structural aspects also need to be considered. By understanding correlations
between crystal structure and disproportionation, we can rationally select the crystalline solid form
of the salt having optimum crystal structure arrangements protecting it against disproportionation
and produce stable salt formulations.
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3.2

Introduction

Formulations containing the salt form of the drug are common. According to the Food and Drug
Administration’s (FDA) orange book database, about half of marketed pharmaceutical products
are available as the salt form [1]. The salt enhances the solubility and bioavailability relative to the
parent free form [2]. In addition, if the free base is a liquid at room temperature, a salt form can be
produced to obtain a crystalline form, providing improved handling during pharmaceutical
manufacturing [3]. The salt form is also desirable when the parent free form is reactive or
undergoes rapid degradation; the salt form often has superior solid-state properties relative to the
free base form, leading to enhanced stability [4, 5]. The two major challenges with the salt
formulation are deliquesce and disproportionation [6]. The former occurs when the salt is highly
hygroscopic and liquification occurs at a critical relative humidity. On the other hand,
disproportion occurs when there is a change in microenvironmental pH, typically resulting from
the presence of certain excipients in the formulations [6].

Disproportionation is a key challenge for pharmaceutical development and a deeper understanding
of important factors impacting this process is required. Disproportionation can result from the
processing operation, the presence of a particular formulation component or some combination
thereof. Unit operation such as high shear wet granulation and compression have been shown to
increase the risk salt to free base conversion [7]. In case of formulation factors, the cause of
disproportionation is dependent on the excipients used as well as the properties of the API salt.
Important factors include basicity of the excipients, particle size, and the surface area of API used
[8]. In addition, environmental factors such as temperature and relative humidity are known to
impact disproportionation [8]. Two physicochemical properties typically used to evaluates the risk
of disproportionation are the compound pka and pHmax [9]. For the salt of a weakly basic API, any
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excipient generating a microenvironmental pH greater than the pHmax of the API salt can
theoretically result in disproportionation. However, the solid state structure of a given salt has not
been taken into wide consideration when considering the disproportionation tendency.

Previous research suggested that the solid state properties of the API salt may play a role in
governing disproportionation. For instance, the amorphous salt of the miconazole mesylate was
shown to be highly prone to disproportionation as compared to crystalline anhydrous form, while,
the dihydrate salt did not show any disproportionation [10]. It was suggested that the molecular
packing in the dihydrate salt hindered disproportionation. This research thus indicated that there
might be a correlation between crystal structure and susceptibility to disproportionation. However,
it is also important to probe the disproportionation at the interface between the reacting solids.
Crystalline salts that appear to be resistant to disproportionation could in principle react to form a
very thin product layer at the surface, which then creates a barrier hindering further reaction. If
this product layer is lower than the analytical detection limit, which is feasible if bulk analysis
techniques are employed, then an incorrect conclusion could be drawn. The formation of a barrier
layer has been reported for other systems during phase transformations [11, 12]. Consequently, it
is important to determine if a given salt crystal structure is truly resistant to disproportionation, or
if the extent of reaction falls below detection limits.

In this study, the disproportionation tendency of severally chemically and structurally diverse salts
of model weakly basic compounds, was evaluated using bulk and surface analytical techniques.
Molecular packing was evaluated using single crystal structures in order to provide insight into
possible structural features that might impact disproportionation tendency. Because previous
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research indicated that miconazole mesylate dihydrate is resistant to disproportionation while the
anhydrate and amorphous forms are susceptible, both hydrates and non-solvated salts were
evaluated. The following compounds were evaluated for disproportionation tendency in the
presence of a basic excipient: pioglitazone HCl, ziprasidone HCl, ziprasidone mesylate, sorafenib
tosylate, and atazanavir sulfate. Each of these salts has a low pHmax (Table 3.1) and hence
theoretically, a high tendency to undergo disproportionation. Powder blends were evaluated using
Raman spectroscopy to determine bulk disproportionation. Atomic force microscopy (AFM) and
scanning electron microscopy (SEM) were employed to study changes occurring at the interface
between the salt crystal and the excipient. A comparison was made between the salt and free base
crystal structures to further identify any constraints which might impact the likelihood of
disproportionation.

3.3

Experimental section

3.3.1 Materials
PIOH was obtained from the Tokyo Chemical Industry Co, Ltd. (Portland, OR). Magnesium
stearate (MgSt) was supplied by Brand Nu Labs (Meriden, CT). Sodium hydroxide (NaOH) and
hydrochloric acid (HCl) were purchased from Fisher Scientiﬁc (Pittsburgh, PA). Ziprasidone
mesylate (ZIPM), ziprasidone hydrochloride (ZIPH), and ziprasidone (ZIP) free base was procured
from Pfizer as a gift. Atazanavir sulfate (ATZS) and sorafenib tosylate (SORT) were obtained
from ChemShuttle (Hayward, CA), while atazanavir (ATZ) and sorafenib (SOR) free base were
obtained from Attix Pharmaceutical (Toronto, Ontario, Canada). All the chemicals were >99%
pure. Ultrapure water was obtained using a Millipore ultrapure water system (Billerica, MA). The
molecular structures of model API salts and the excipients are shown in Figure. 3.1.
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Figure 3.1 Chemical structures of PIOH, ZIPH, ZIPM, ATZS, SORT, and MgSt.

Amorphous ATZS was prepared by the solvent evaporation method. Briefly, a concentrated
methanolic solution of ATZS (150 mg/mL) was poured onto a glass dish and solvent was rapidly
evaporated using dry nitrogen gas. The obtained glassy material was removed using a spatula and
stored in a sealed vial.

To obtain pioglitazone (PIO) free base, an excess amount of PIOH was slurried in 1 M NaOH
solution at 700 rpm for 3 hr, followed by vacuum filtration, washing with water, and air drying.
The resulting powder was collected and stored in an air-tight container.
3.3.2 Methods
3.3.2.1 Preparation of binary mixtures for bulk disproportionation study
Each salt form (PIOH, ZIPH, ZIPM, SORT, ATZS) was mixed at a 50% (w/w) ratio with the
model excipient, MgSt. 50 mg of each salt form was geometrically mixed with 50 mg of MgSt
using a spatula. The mixtures were prepared in triplicate. All samples were then stored in open
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vials at 75 % RH and 40 °C, except, ATZS samples, which were stored at 85 % RH and 40 °C. In
addition, pure salts were also stored at the same conditions.
3.3.2.2 Raman Spectroscopy
Raman spectroscopy was used to monitor the salt disproportionation. A RamanRxn2 Analyzer
(Kaiser Optical Systems, Inc., Ann Arbor, MI) with a PhAT probe, as described previously [10],
was used for analysis. For the light source, a 785 nm high power NIR diode laser (Invictus) was
used. A laser spot size of 6 mm was used to deliver back scattered radiation to the base unit via
the fiber bundle of the PhAT probe. The instrument was calibrated as described previously [10].
A specially designed sample holder was used to obtain reproducible results. the CCD detector
(Charge coupled device) was cooled to −40 °C to reduce the offset in the baseline and all spectra
were corrected by a dark subtraction. To generate each spectrum, 6 scans were accumulated at an
exposure time of 10 s each with a laser power of 400 mW.
3.3.2.3 Preparation of salt solutions for spin coating to produce crystal films
Solutions of ZIPH (12 mg/mL) and ZIPM (25 mg/mL) were prepared by dissolving the appropriate
amount of salt in a MeOH:DCM (1:1) mixture at 40 °C. The PIOH solution (150 mg/mL) was
prepared in MeOH at 40 °C, whereas, the SORT solution (11 mg/mL) was prepared in a
MeOH:H2O (5:1) mixture at 55 °C. A solution of ATZS (150 mg/mL) was prepared in MeOH at
25 °C.
3.3.2.4 Film preparation for disproportionation study
Films of different salt solution were prepared using a KW-4A spin coater (Chemat Technology
Inc., Northridge, CA). Silicon wafers, thallium bromoiodide (KRS-5), and glass substrates were
used to prepare films for Atomic force microscopy (AFM), Fourier Transform infrared (FTIR)
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spectroscopy, and polarized light microscopy (PLM) analysis, respectively. Silicon wafers with a
mirror finish were cut into pieces of approximately 1 cm2 in size and were taped on steel stubs for
preparing films for AFM, scanning electron microscopy (SEM), and Energy-dispersive X-ray
spectroscopy (EDX) analysis. KRS-5 and glass slides were also cut into pieces of around 1 cm2,
which were used for FTIR and PLM analysis, respectively. Twenty-five microliters of salt solution
was placed on the substrate which was subsequently spun for 6 s at 50 rpm, followed by 30 s at
1500 rpm. The resultant films were stored at 75 % RH and 40 °C for 2 days to obtain crystalline
salt films, with the exception of ATZS. To obtain amorphous film of ATZS, the films were stored
at 85 % RH and 40 °C, whereas to obtain a crystalline ATZS film, films were stored in enclosed
chamber saturated with an ACT:IPA (1:1) solvent mixture at 40 °C for 2 days followed by storage
at 85 % RH and 40 °C for 2 days.
3.3.2.5 Atomic Force Microscopy (AFM)
Topographical images of film samples were obtained using a nanoIR2 AFM-IR instrument
(Anasys Instruments, Inc., Santa Barbara, CA). Contact mode NIR2 probes (Model: PR-EX-NIR2,
Anasys Instruments, Santa Barbara, CA) were used. To obtain AFM topographical images by
contact mode, an x and y resolution of 256 points and a scan rate of 0.5 kHz was used. To collect
and analyze these images, the Analysis Studio software (version 3.10.5539, Anasys Instruments.,
Santa Barbara, CA) was used. The thickness of the films were determined by making a scratch on
the film with a razor blade followed by an AFM scan across the scratch.
3.3.2.6 Polarized Light Microscopy (PLM)
Films prepared on a glass substrate were utilized for PLM analysis. Glass substrates with a salt
film were mounted onto the stage of the Eclipse E600 POL microscope. The images were obtained
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by microscope equipped with a DS Fi1 camera (Nikon Corporation, Tokyo, Japan) using crosspolarized light in transmittance mode as described previously [13].
3.3.2.7 Fourier Transform Infrared Spectroscopy (FTIR)
FTIR spectra of the various films were collected using a Bruker Vertex 70 instrument (Bruker Co.,
Billerica, MA) equipped with a transmittance sample holder [14]. OPUS software (Bruker Co.,
Billerica, MA) was used for data collection and analysis. FTIR spectra were generated by placing
film samples prepared on KRS-5 substrates into transmittance accessory, followed by
accumulating 64 scans at a resolution of 4 cm−1.
3.3.2.8 Electron dispersive spectroscopy (EDS) coupled with scanning electron microscopy
(SEM)
The surface texture and elemental distribution of exposed and unexposed regions of the films were
determined by EDS using a field emission SEM (Quanta SEM, FEI Co., Hillsboro, OR, USA)
equipped with an EDS detector [15]. The samples were first coated with Platinum (~2 nm
thickness) using a Cressington sputter coater (208HR, Cressington Scientific Instruments,
Watford, UK). The SEM images were acquired first and then the EDS analysis was then performed
at an accelerating voltage of 10 kV to collect elemental data. The resulting images were then
analyzed using an Oxford Inca system (Oxford Instruments Analytical, Buckinghamshire, UK).
Each experiment was performed in triplicate to determine an average value for elements in the
samples.
3.3.2.9 X-ray Powder Diffraction (XRPD).
Diffraction patterns of various samples were collected using a Rigaku SmartLab (XRD 6000)
diﬀractometer (The Woodlands, TX) with Bragg−Brentano mode as described previously [16].
CuKα radiation (λ = 1.5405 Å) was used. About 40 mg of each sample was placed onto a glass
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sample holder. Diffraction data were recorded at room temperature between 10° to 40° 2θ with a
step size of 0.02° with a scan time of about 8 minutes per sample.
3.3.2.10 Preparation of MgSt disk
The MgSt disks were prepared using a Specac IR press (Grasby Specac, Kent, UK). About 200
mg of MgSt powder was added to a die of 10 mm diameter followed by addition of about 50 mg
of ethyl cellulose, which aids removal of the MgSt disk from the punch. The material was then
compressed at 700 psi for 3 sec to obtain the bilayer disk. The MgSt containing part was contacted
with the crystal films for the interfacial disproportionation investigations.
3.3.2.11 Solubility determination
The slurry method was used to determine the solubility of salt and/or free base with samples
measured in triplicate [14]. An excess amount of solids were allowed to slurry in water for 48 hr
at 25 °C. Optima L-100 XP ultracentrifuge (Beckman Coulter, Inc., Brea, CA) was then used at
35,000 rpm for 25 min to remove the excess solid. An Infinity Series high performance liquid
chromatography (HPLC) system (Agilent 1290, Agilent Technologies, Santa Clara, CA) was then
used to determine the concentration in the supernatant. An Inertsil® ODS-3 C18 column with
dimensions of 5 μm, 4.6 × 100 mm (GL Sciences Inc., Rolling Hills Estates, CA) was used. The
mobile phase was prepared by mixing water and acetonitrile (1:1, v/v) along with 0.1%
trifluroacetic acid. A ﬂow rate of 1 mL/min and an injection volume of 10 μL were used. The
ultraviolet (UV) detector set at 220 nm was used to monitor the elution of the compound. A
calibration curve (R2 value of 0.995) was used to determine the concentration of each sample.
Dilution with mobile phase was performed to obtain concentration values within the range of the
calibration plot.
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3.3.2.12 Determination of pHmax
The pHmax for different salt forms were obtained using the following equation [17, 18].

p𝐻𝑚𝑎𝑥 = p𝐾𝑎 + log

𝑆0
√𝐾𝑠𝑝

(14)

Where, the pKa is related to the acid dissociation constant (Ka) of the protonated drug, S0 is the
intrinsic solubility of the free base, and Ksp is the solubility product for the salt. The previously
reported pKa and solubility values were used to calculate the pHmax.

3.4

Results

3.4.1 Solid form identification and single crystal structure determination
To analyze the polymorphic form and phase purity of the various model salts, XRPD was
performed. The PIO free base obtain from the PIOH, showed an XRPD pattern well matched to
the reference powder pattern, [19]. This indicates successful formation of PIO free base (Figure
S1). The XRPD patterns (Figure S1) indicated that the PIOH exists as pure polymorphic Form I
and has no detectable free base. Similarly, XRPD analysis was carried out for all other samples
(Figure S1 and S2). The Cambridge crystal structure database (CSD) was used to identify the solidstate form of the salt and free base used in this study. ZIPH was found to be present as the
monohydrate form (Figure S1), while ATZS and SORT were identified as anhydrous forms
(Figure S2). The crystal structure of ZIPM and the free base forms of ATZ and PIO were not
available in the CSD. Therefore, single crystals of these material were produced and analyzed by
single crystal x-ray diffraction to obtain their structure (described in detail in supporting
information). The data indicated that ZIPM is a trihydrate while ATZ and PIO free base were
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anhydrous (Figure S1 and S2). XRPD patterns of all salts were then compared with their respective
free bases. The results indicated that all salts were present in pure form, without any detectable
free base (Figure S1 and S2). To observe the effect of amorphization on the disproportionation
reaction, ATZS amorphous salt was prepared by solvent evaporation method. XRPD analysis
indicated an absence of any crystalline peaks in the ATZS amorphous salt material (Figure S3).
The neat amorphous form of ATZS was found to remain stable at the experimental conditions
employed (Figure S3).
3.4.2 pHmax determination
Previous research indicates that the pHmax is a critical factor which governs the rate and extent of
disproportionation [20, 21]. Therefore, it was essential to evalute pHmax values for the salts used in
this study. Based on experimental and/or literature data and utilizing equation 1, pHmax values for
various salts were determined and are reported in Table 3.1.

Table 3.1 pKa and pHmax values for various salts
Solid Form
pKa
pHmax
a
PIOH
5.2
3.0b
ZIPH
6.5c
3.4d
c
ZIPM
6.5
2.4d
ATZS
4.7e
2.3f
g
SORT
4.9
3.327h
a
pka of PIO free base was obtained from [22].
b
obtained from [23].
c
pka of ZIP free base was obtained from [24].
d
obtained using the experimentally determined solubility value of 0.000078 mg/mL, 0.09431
mg/ml, and 0.899 mg/mL for ZIP free base, ZIPH, and ZIPM, respectively.
e
pka of ATZ free base was obtained from [25].
f
obtained using the experimentally determined solubility value of 1.60 mg/mL and 0.0057 mg/mL
for ATZ free base and ATZS, respectively.
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g

pka of SOR free base was obtained from [22].
solubility of SOR free base (0.0000359 mg/mL) and SORT (0.00152 mg/mL) were obtained
from [22].
h

3.4.3 Disproportionation in binary blends with MgSt
To check which model API salts are prone to disproportionation, a binary blend of each salts with
the basic excipient, MgSt, were prepared. These blends were stored at accelerated stability
conditions. Raman spectroscopy was used to determine the event of disproportionation. Amongst
the samples, PIOH showed disproportionation as noted by a decrease in the intensity of the
characteristic salt peak at ~1638 cm-1 (Figure 3.2A), which is consistent with previous results [26].
In addition, the amorphous form of ATZS was also found to disproportionate when stored with
MgSt, as indicated by formation of ATZ free base peaks. On the other hand, ZIPH, ZIPM, ATZS
crystalline, and SORT salts did not show any disproportionation (Figure 3.2), even after 14 days
of storage at accelerated conditions with MgSt. XRPD analysis of ZIPH, ZIPM, ATZS crystalline,
and SORT salt samples after storage showed an absence of free base peaks (Figure S4), consistent
with the Raman analysis. In contrast, PIOH and amorphous ATZS showed the presence of
characteristic free base diffraction peaks (Figure S4). Furthermore, the control, neat API salt
powders (without MgSt) did not show any disproportionation, with the exception of PIOH, which
showed slight disproportionation after 14 days, consistent with previous observations [26].
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Figure 3.2 Raman spectra for samples corresponding to (A) PIOH, (B) ZIPH, (C) ZIPM, (D)
ATZS, (E) ATZS amorphous, and (F) SORT. Where (a) pure salt, (b) salt + MgSt physical
mixture (c) salt + MgSt stored at accelerated condition for 2 days, (d) salt + MgSt stored at
accelerated condition for 14 days (e) respective pure free base.
3.4.4 Preparation and characterization of salt films
Films of various API salts were prepared to study correlations between the change in salt
crystalline surface topography and disproportionation. To identify the solid form of salt being
generated in the film, as well as to analyze the occurrence or absence of disproportionation, films
were prepared on different substrates. Glass, KRS-5, and Silicon wafers substrates were used to
prepare films for characterization with PLM, FTIR, and AFM analysis, respectively.
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The salt films were prepared by spin coating on various substrates and then pre-treated by various
conditions to obtain desired solid form of the salt. As the films obtained by spin coating were too
thin to perform XRPD, instead of spin coating, thicker samples were also obtained using similar
experimental conditions, and the obtained material was then analyzed by XRPD. In addition, FTIR
was also used to compare the solid state form of salt films obtained on the KRS-5 substrates. The
FTIR spectra for each salt film were comparable to the spectra of their respective reference powder
samples. Both XRPD (Figure S5) and FTIR (Figure 3.3A-F) results showed that desire solid forms
of salt were obtained, which the same as those used for binary blend disproportionation studies.

FTIR was also used to determine the occurrence of disproportionation in salt film after contact
with a MgSt disk. ZIPH, ZIPM, crystalline ATZS, and SORT did not show any changes after
exposure to MgSt, indicating an absence of disproportionation (Figure 3.3). On the other hand, the
spectra for PIOH and amorphous ATZS films were changed after contact with MgSt, and showed
peaks corresponds to the free base forms (Figure 3.3).
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Figure 3.3 FTIR spectra of samples corresponding to (A) PIOH, (B) ZIPH, (C) ZIPM, (D)
ATZS, (E) ATZS amorphous, and (F) SORT. Where (a) pure free base, (b) pure salt, (c)
unexposed to MgSt, and (d) exposed to MgSt
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After having established which films were able to undergo disproportionation and which were not,
changes in the morphology and texture of the film after disproportionation were evaluated. First,
to identify any gross visual change in the salt films upon disproportionation, PLM was performed
on salt films prepared on glass substrates. First the MgSt disk was placed in contact with each film,
which were then stored under at accelerated storage conditions. PLM images were taken for the
films, taking images of unexposed and MgSt-exposed regions. PLM images of the initial, non
MgSt-exposed film showed that most systems showed a spherulite morphology, with the exception
of the ATZS amorphous film (Figure 3.4). The presence of birefringence for unexposed films of
PIOH, ZIPH, ZIPM, ATZS, and SORT confirms their crystalline nature, while unexposed
amorphous ATZS films did not showed any birefringence. Analysis of PLM images for films
exposed to MgSt indicated no change in morphology or birefringence for ZIPH, ZIPM, ATZS, and
SORT. In contrast, large spherulites initially present in PIOH films were converted to smaller
regions of crystalline material with altered birefringence, while exposed amorphous ATZS
amorphous films showed the appearance of small birefringent regions.
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Figure 3.4 PLM images of samples for (A) PIOH, (B) ZIPH, (C) ZIPM, (D) ATZS, (E) ATZS
amorphous, and (F) SORT in the unexposed and MgSt exposed regions.
3.4.5 AFM analysis
To monitor the changes in surface topography of various API salt films after being exposed to
MgSt, AFM analysis was carried out. The data shows that the PIOH film show a smooth
morphology in the unexposed region, while a dramatic change in the topography for the MgSt
exposed region was observed (Figure 3.5). The films of ZIPH, ZIPM, crystalline ATZS and SORT
films did not show any difference in their topography for MgSt exposed or unexposed regions
(Figure 3.5). However, the ATZS amorphous film also showed a change in the topography in the
MgSt exposed regions compared to unexposed region of the film.

88

Figure 3.5 AFM (deflection) images of samples for (A) PIOH, (B) ZIPH, (C) ZIPM, (D)
ATZS, (E) ATZS amorphous, and (F) SORT in the unexposed and MgSt exposed regions.
3.4.6 SEM/EDX analysis
To further confirm the presence or absence of disproportionation in the films, SEM/EDX was used
as an orthogonal technique. The SEM data showed that various spherulite morphologies were
obtained for crystalline films of PIOH, ZIPH, ZIPM, ATZS, SORT. As seen from the PLM study
the PIOH spherulites were very large and SEM images indicated that they have very smooth
surface (Figure 3.6A). The surface of the ZIPH and ZIPM spherulites showed plate-like
morphologies, while the surface of ATZS films showed needle-like spherulite morphology (Figure
3.6B-D). On the other hand, the surface of the amorphous ATZS film was found to be smooth
(Figure 3.6E). The SORT film showed spherulite which are large plate like crystalline in nature
(Figure 3.6F).
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The morphology of the PIOH and the amorphous ATZS film is different in the exposed region
compared to that of the unexposed region. In both case small spherulites emerged in the portion of
the film exposed to the MgSt. In contrast, the surface of ZIPH, ZIPM, crystalline ATZS, and,
SORT did not show any differences in morphology between exposed and unexposed regions. SEM
analysis of the MgSt disk was also performed. The surface of the disk found to have large
irregularly shaped plate like structures, which is characteristic of MgSt (Figure S6). There is no
morphology change for MgSt before or after contacting with various salt films.

Figure 3.6 SEM images of samples for (A) PIOH, (B) ZIPH, (C) ZIPM, (D) ATZS, (E) ATZS
amorphous, and (F) SORT in the unexposed and MgSt exposed regions.

EDX was performed to analyze any change in the chemical profile for MgSt exposed and
unexposed regions (Table 3.2). The obtained elemental distribution data are similar to their
respective theoretically predicted values based on molecular formula (Table S1). The data showed
that for the case of PIOH, the unexposed region has high chlorine amount, while the exposed
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region showed negligible amount of chlorine (Table 3.2). In contrast, the other films do not show
much difference in the elemental distribution between MgSt exposed and unexposed regions.

EDX analysis was also performed on the MgSt disk. Only the MgSt exposed to PIOH showed
presence of Cl in its elemental distribution (Table S2). All other samples of MgSt exposed to
different salt films had elemental distribution similar to that of the unexposed MgSt (Table S2).
The elemental distribution of unexposed MgSt showed slightly higher amounts of O and Mg,
compared to the theoretically predicted values. This could be due to contamination with MgO.
Table 3.2 Elemental distribution obtained by EDX of various salt films

Element

PIOH
Unexposed

Exposed

Element

ATZS
Unexposed

C
N
O
S
Cl

74.5 ± 0.3
6.4 ± 0.2
8.1 ± 0.1
6.9 ± 0.1
4.1 ± 0.1

78.1 ± 0.2
6.0 ± 0.1
7.6 ± 0.1
7.8 ± 0.1
0.1 ± 0.1

C
N
O
S

70.1 ± 0.5
11.7 ± 0.3
16.2 ± 0.1
2.0 ± 0.1

Element

ZIPH
Unexposed

Exposed

C
N
O
S
Cl

71.4 ± 0.1
12.7 ± 0.1
6.4 ± 0.2
3.2 ± 0.2
6.3 ± 0.4

71.2 ± 0.4
12.9 ± 0.2
6.3 ± 0.1
3.5 ± 0.1
6.1 ± 0.2

Element

ZIPM
Unexposed

C
N
O
S
Cl

62.7 ± 0.4
12.1 ± 0.4
16.9 ± 0.2
5.2 ± 0.2
3.1 ± 0.1

Exposed
70.7 ± 0.4
10.5 ± 0.1
16.6 ± 0.2
2.2 ± 0.1

ATZS amorphous
Element
Unexposed Exposed
C
N
O
S

71.1 ± 0.4
11.4 ± 0.2
15.6 ± 0.2
1.9 ± 0.1

Exposed

Element

SORT
Unexposed

62.3 ± 0.4
11.8 ± 0.3
17.5 ± 0.3
5.5 ± 0.1
2.9 ± 0.2

C
N
O
Cl
F
S

70.8 ± 0.5
9.6 ± 0.3
7.8 ± 0.2
2.6 ± 0.1
6.5 ± 0.2
2.7 ± 0.2

70.9 ± 0.3
10.9 ± 0.2
16.7 ± 0.2
1.5 ± 0.1

Exposed
70.4 ± 0.4
9.5 ± 0.2
7.6 ± 0.3
2.8 ± 0.2
6.9 ± 0.2
2.8 ± 0.1
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3.4.7 Single crystal structure analysis
To identify the presence or absence of a direct salt bridge in the structure, the single crystal
structure was obtained from the CSD or determined experimentally and analyzed using Mercury.
The data shows that PIOH, ATZS, and SORT have a direct salt bridge in their crystal structure,
while ZIPH and ZIPM do not have a direct salt bridge (Figure 3.7). Furthermore, in the structure
of the ATZS, the salt bridge is shielded by two of the adjacent biphenyl rings, while in the structure
of SORT, instead of one salt bridge linking API and counter ion, there is a dual salt bridge.

Figure 3.7 Crystal structures of various salts showing interaction of API and respective
counterion for (A) PIOH, (B) ZIPH, (C) ZIPM, (D) ATZS, and (E) SORT.

To compare the conformational differences in the molecule of API in the salt and free base form,
their crystal structures were obtained from CSD or determined experimentally. The result of the
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analysis showed a slightly larger extent of conformation difference was observed for PIO/PIOH
and for ATZ/ATZS compared to all other structures (Figure 3.8).

Figure 3.8 Overlay of API conformation in salt (red) and their free base (blue) in single crystal
structure of (A) PIOH, (B) ZIPH, (C) ZIPM, (D) ATZS, and (E) SORT and their respective
free base form.

To evaluate any differences in the unit cell parameter between salts and free base, the structures
of the unit cells were overlaid and are presented in Figure 3.9, while their parameters are presented
in Table 3.3. The data indicated that salt to free base conversion in the case of the PIOH could be
possible by simple gliding of the molecule without involving much rotation over the central axis
of molecule. In the case of ZIPH, ZIPM, ATZS, and SORT, the API molecule must rotate around
90° - 180° to convert to free base unit cell structure.
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Figure 3.9 Overlay of the unit cell of salt (red) and free base (blue) for (A) PIOH, (B) ZIPH,
(C) ZIPM, (D) ATZS, and (E) SORT and their respective free base form.
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Table 3.3 Unit cell parameters for various salts and free bases
Parameter
Refcode
Space group
a
b
c
α
β
γ

PIOH
FAYDUF

PIO
FAYDUF03

ZIPH
ZIPM
OMAKAQ01 OMAKAQ04

ZIP
VUJRUO

Monoclinic, P21

Monoclinic, P21/c

Triclinic, P1

Monoclinic, P21/n

Monoclinic, P21/a

10.0696 (17) Å

4.6249 (3) Å

7.250103 (28) Å

13.709 (6) Å

7.377 (8) Å

9.4318 (16) Å

18.4928 (10) Å

10.98666 (8) Å

11.595 (4) Å

8.038 (3) Å

10.1752 (19) Å

22.4002 (12) Å

14.07187 (14) Å

16.764 (8) Å

33.627 (6) Å

90°

90°

83.4310 (4)°

90°

90°

95.178 (14)°

92.016 (3)°

80.5931 (6)°

103.496 (16)°

95.60 (4)°

90°

90°

87.1437 (6)°

90°

90°

Parameter
Refcode
Space group
a
b
c
α
β
γ

ATZS
LUQREW

ATZ
LUQREW01

SORT
AKENUA

SOR
AKENOU

Triclinic, P1

Monoclinic, P21

Monoclinic, P21/c

Monoclinic, P21/c

9.861 (5) Å

15.2650 (18) Å

21.276 (4) Å

8.1587 (16) Å

29.245 (6) Å

5.8604 (6) Å

9.1160 (17) Å

9.8055 (19) Å

8.327 (2) Å

21.365 (2) Å

16.077 (3) Å

27.758 (5) Å

93.56 (2)°

90°

90°

90°

114.77 (3)°

95.966 (3)°

108.143 (3)°

94.358 (3)°

80.49 (3)°

90°

90°

90°

3.5

Discussion

Salt disproportionation can result in reduced dissolution and solubility of a formulation. Extensive
research has been conducted previously to identify the key factors affecting the salt
disproportionation process. These factors can be related to either the excipient or the API used in
the salt formulation, or some combination thereof. Excipient slurry pH and particle size plays a
major role in governing disproportionation [8, 20]. For the API, properties such as pHmax and
particle size have been shown to affect disproportionation [4, 8, 20]. Aside from formulation
factors, environmental conditions such as temperature and humidity, and processing operations
such as wet granulation have been shown to impact disproportionation [8, 20, 27]. However, no
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research has been previously done to establish a correlation between the crystal structure of the
salt and disproportionation.

Accoring to previous studies, pHmax is one of the critical factors which governs the rate and extent
of disproportionation [20, 21]. Herein, since we wanted to evaluate the effect of structural
differences on disproportionation, the model salts were selected such that they have similar values
of pKa and the pHmax (Table 3.1). The results show that the calculated pHmax value for the model
salts are close to each other. Bulk disproportionation studies using MgSt as the basic excipient
indicated that only PIOH and amorphous ATZS underwent disproportionation, while intriguingly,
all other API salts appeared to be resistant to disproportionation. ATZS and ZIPH have different
space groups for the salt and free base forms and this may influence the ease of disproportionation,
while, in the case of PIOH, both salt and free base are present in same space group, facilitating
easy disproportionation. However, this was not found to be case for ZIPM and SORT, where even
though salt and free base are present in the same space group, disproportionation was not observed.

A more detailed crystal structure analysis revealed that PIOH has a direct salt bridge, while ZIPM,
ZIPH did not. This observation may suggest that the absence of direct salt bridge renders a salt
form more resistant against disproportionation. In both these crystal structures, the API molecule
is associated with the counter ion via a water molecule. A similar crystal structure pattern was also
seen in case of miconazole mesylate dihydrate form [10].

In case of the ATZS, the crystal structure showed a unique pattern among the various salts
investigated where the salt bridge is shielded between the two adjacent biphenyl rings, conceivably
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hindering disproportionation. In the case of SORT, crystal structure analysis indicated that it has
a dual salt bridge between the API molecule its counterion. The double hydrogen bonds, may
increase resistance of SORT to disproportionation.

To understand other structural features which could have prevented or facilitated the salt to free
base conversion of these salts, a comparison of the salt and their respective free base crystal
structures was carried out. The conformational analysis indicated that amongst all structure, for
conversion of salt to free base form, ATZS molecules must undergo greater conformational
changes to accommodate free base structure. This is another reason why it is difficult to
disproportionate ATZS in the crystalline form.

The comparison of unit cells of salt and free base data indicated that unit cell structure of the PIOH
can easily transform to the PIO unit cell by simple gliding of the molecule without involving much
rotation over the central axis of molecule. In contrast, in the case of ZIPH, ZIPM, ATZS, and
SORT, the API molecule must rotate around 90° -180° to convert to the free base unit cell structure.
This could be another reason for these salts being resistant to disproportionation.

The comparison of unit cell space group indicated that if there is change in the space group
involved during the process of salt to free base conversion, then it is less likely that these salts will
disproportionate. For instant, for a salt in the triclinic space group, it would be difficult to
disproportionate if their respective free base is in the monoclinic form.
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During disproportionation, the salt form is converts to free base. As this process involves
recrystallization of the free base from the salt form, there should be change in the surface of the
salt crystals if they undergo disproportionation. The AFM and SEM studies of the surface
topography clearly show a lack of reaction for ZIPH, ZIPM, SORT, and crystalline ATZS. Thus,
it is apparent that disproportionation is not occurring for these systems, rather than occurring
simply in a very thin surface layer which then poisons further reaction. This observation confirms
that some systems are indeed resistant to disproportionation.

EDX was also used as a technique to identify disproportion. However, it is important to understand
that this technique will only be able to identify disproportionation, if the element present in the
counter ion is not present in API and/or there is change in the ratio of the elements upon
disproportionation. In addition, if the byproducts of disproportionation are accumulated at the
surface then EDX will not be able to differentiate the stable and disproportionated regions of the
film. In this study, the disproportionation of PIOH film was clearly identified by EDX as its counter
ion has unique Cl element and after the disproportionation, Cl left the film. However, EDX did not
showed much differences in the stable or disproportionated amorphous ATZS films. This could be
due to byproduct of the disproportionation accumulating at the surface.

3.6

Conclusions

Utilizing various model salts with similar pKa and pHmax values, we have demonstrated that the
crystal structure of the salt appears to play a major role in determining the susceptibility
disproportionation when mixed with basic excipients and stored at accelerated stability conditions.
Interestingly, salts which lacks a direct salt bridge between API and the counter ion appear to be
resistant to disproportionation. Differences in the molecular arrangement in the salt crystal versus
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in the free base crystal may also play an important role. Our studies clearly indicate that the role
of crystal packing in disproportionation tendency should be further investigated with the ultimate
goal of improving the robustness of salt formulations.

3.7
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3.8

Supporting information

3.8.1 Supporting methods
3.8.1.1 Single crystal X-ray diffraction
Single crystal X-ray measurements were conducted on a Bruker Quest Instrument with a Cu-K
X-ray microsource ( = 1.54178 Å) with a laterally graded multilayer (Goebel) mirror for
monochromatization. Single crystals were mounted on Mitegen microloop mounts using a trace of
mineral oil and cooled in-situ to 100(2) K for data collection. A Photon2 CMOS area detector and
an Oxford Cryosystems low temperature device were used for this purpose.
Data were collected, reflections were indexed and processed, and the files scaled and corrected for
absorption using APEX3 [1]. The space groups were assigned, and the structures were solved by
direct methods using XPREP within the SHELXTL suite of programs [2] and refined by full matrix
least squares against F2 with all reflections using Shelxl2018 [3] using the graphical interface
Shelxle [4]. If not specified otherwise H atoms attached to carbon and nitrogen atoms and hydroxyl
hydrogens were positioned geometrically and constrained to ride on their parent atoms, with
carbon hydrogen bond distances of 0.95 Å for and aromatic C-H, 1.00, 0.99 and 0.98 Å for
aliphatic C-H, CH2 and CH3 moieties, respectively. Methyl H atoms were allowed to rotate but not
to tip to best fit the experimental electron density. Uiso(H) values were set to a multiple of Ueq(C)
with 1.5 for CH3, and 1.2 for C-H units, respectively. Complete structures in CIF format have been
deposited with the Cambridge Crystallographic Database. CCDC contains the supplementary
crystallographic data for this paper. The data can be obtained free of charge from The Cambridge
Crystallographic Data Centre via www.ccdc.cam.ac.uk/structures.
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Table 1. Experimental details for single crystal structure of ziprasidone mesylate trihydrate
OMAKAQ04
Crystal data
Chemical formula

C21H22ClN4OS·CH3O3S·3(H2O)

Mr

563.08

Crystal system, space Monoclinic, P21/n
group
Temperature (K)

150

a, b, c (Å)

13.709 (6), 11.595 (4), 16.764 (8)

 (°)

103.496 (16)
3

V (Å )

2591.0 (18)

Z

4

Radiation type

Mo K

 (mm-1)

0.36

Crystal size (mm)

0.16 × 0.11 × 0.04

Data collection
Diffractometer

Bruker
diffractometer

AXS

D8

Quest

CMOS

Absorption correction

Multi-scan
SADABS 2016/2: Krause, L., Herbst-Irmer, R., Sheldrick G.M. & Stalke
D., J. Appl. Cryst. 48 (2015) 3-10

Tmin, Tmax

0.598, 0.746

No.
of
measured, 26891, 6236, 3643
independent
and
observed [I > 2(I)]
reflections
Rint

0.091

(sin /)max (Å-1)

0.667

Refinement
R[F2 > 2(F2)], wR(F2), 0.070, 0.191, 1.03
S
No. of reflections

6236

No. of parameters

406

No. of restraints

166

H-atom treatment

H atoms treated by a mixture of independent and constrained refinement

max, min (e Å-3)

0.56, -0.60
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Table 2. Experimental details for single crystal structure of pioglitazone and atazanavir free base
FAYDUF03

LUQREW01

Chemical formula

C19H20N2O3S

C38H52N6O7

Mr

356.43

704.85

Crystal data

Crystal system, space Monoclinic, P21/c
group

Monoclinic, P21

a, b, c (Å)

4.6249 (3), 18.4928 (10), 22.4002 15.2650 (18), 5.8604 (6), 21.365 (2)
(12)

 (°)

92.016 (3)

95.966 (3)

V (Å3)

1914.64 (19)

1900.9 (4)

Z

4

2

 (mm-1)

1.66

0.70

Crystal size (mm)

0.55 × 0.02 × 0.02

0.55 × 0.02 × 0.02

0.359, 0.754

0.522, 0.753

Data collection
Tmin, Tmax

No.
of
measured, 11942, 3731, 3028
independent
and
observed [I > 2(I)]
reflections

14005, 6742, 3881

Rint

0.101

0.137

(sin /)max (Å-1)

0.626

0.611

Refinement
R[F2 > 2(F2)], wR(F2), 0.073, 0.178, 1.12
S

0.070, 0.165, 0.95

No. of reflections

3731

6742

No. of parameters

342

519

No. of restraints

479

161

H-atom treatment

H-atom parameters constrained

H atoms treated by a mixture of
independent
and
constrained
refinement

max, min (e Å-3)

0.46, -0.32

0.25, -0.30

Absolute structure

–

Classical Flack method preferred
over Parsons because s.u. lower.

Absolute
parameter

structure –

0.3 (4)
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3.8.2 Supporting figures

Figure S1. XRPD patterns for samples of (A) PIOH, (B) PIO FB, (C) ZIPH, (D) ZIPM, (E)
ZIP FB. Where (a) experimental and (b) calculated from single crystal structure.
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Figure S2. XRPD patterns for samples of (A) ATZS, (B) ATZ FB, (C) SORT, and (D) SOR
FB. Where (a) experimental and (b) calculated from single crystal structure.
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Figure S3. XRPD spectra of ATZS amorphous (a) immediately after preparation and (b) stored
at 85 % RH and 40 °C for 14 days.

Figure S4. XRPD spectra of various salt + MgSt stored at accelerated condition for 14 days.
(a) PIOH, (b) ZIPH, (c) ZIPM, (d) ATZS, (e) ATZS amorphous, (f) SORT, and (g) MgSt only.
Solid arrows indicate characteristic peak of respective free base and dotted arrows indicate
characteristic peaks of respective salts.
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Figure S5. XRPD spectra of solid form obtained from conditions representing film formation.
(a) PIOH, (b) ZIPH, (c) ZIPM, (d) ATZS, (e) ATZS amorphous, and (f) SORT. Arrows indicate
characteristic peaks of each salt.

Figure S6. A representative SEM image of MgSt surface.
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3.8.3 Supporting tables
Table S1. Theoretical elemental distribution for various salts (Hydrogen atoms were omitted)

PIOH
Element
Unexposed
C19H21ClN2O3S
C
N
O
S
Cl

73.1
7.7
11.5
3.9
3.9

Exposed
C19H20N2O3S

Element

76
8
12
4
0

C
N
O
S

ZIPH
Element
Unexposed
Exposed
C21H22Cl2N4OS
C21H21ClN4OS
H2 O
C
N
O
S
Cl

70
13.3
6.7
3.3
6.7

75
14.3
3.6
3.6
3.6

ZIPM
Element
Unexposed
Exposed
C22H24ClN4OS2
C21H21ClN4OS
3(H2O)
C
N
O
S
Cl

61.1
11.1
19.4
5.6
2.8

75
14.3
3.6
3.6
3.6

Element

C
N
O
S

Element

ATZS
Unexposed
C38H54N6O11S
67.9
10.7
19.6
1.8

Exposed
C38H52N6O7
74.5
10.7
13.7
0

ATZS amorphous
Unexposed
Exposed
C38H54N6O11S

C38H52N6O7

67.9
10.7
19.6
1.8

74.5
10.7
13.7
0

SORT
Unexposed

Exposed

C28H24ClF3N4O6S C21H16ClF3N4O3
C
N
O
Cl
F
S

70
10
7.5
2.5
7.5
2.5

65.6
12.5
9.4
3.1
9.4
0
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Table S2. Theoretical and EDX determined elemental distribution for MgSt disk

Theoretical MgSt
Mg(C18H35O2)2

Element

Unexposed MgSt

Element

C

C

O
Mg

82.8 ± 0.5
12.7 ± 0.2
4.5 ± 0.2

O
Mg

88.4
9.3
2.3

Element

Exposed to PIOH

Element

Exposed to ATZS

C
O
Mg
Cl

78.6 ± 0.6
13.0 ± 0.3
5.1 ± 0.3
3.3 ± 0.4

C
O
Mg
S

81.6 ± 0.6
14.0 ± 0.3
4.4 ± 0.2
0

Element

Exposed to ZIPH

Element

Exposed to ATZS
amorphous

C
O
Mg
Cl

83.5 ± 0.5
11.9 ± 0.4
4.6 ± 0.3
0

C
O
Mg
S

83.4 ± 0.5
12.5 ± 0.2
4.1 ± 0.2
0

Element

Exposed to ZIPM

Element

Exposed to SORT

C
O
Mg
S

82.7 ± 0.4
12.8 ± 0.3
4.5 ± 0.2
0

C
O
Mg
S

82.6 ± 0.6
12.9 ± 0.4
4.4 ± 0.2
0
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EFFECT OF EXCIPIENT MOBILITY, WATER
ACTIVITY, AND WATER CONTENT ON THE
DISPROPORTIONATION OF A PHARMACEUTICAL SALT

4.1

Abstract

Excipients are crucial components of most pharmaceutical formulations. In the case of a solid oral
dosage formulation containing the salt form of a weakly ionizable drug, excipient selection is
critical, as some excipients are known to cause salt disproportionation (conversion of salt to the
free form). Therefore, robust formulation design necessitates an in-depth understanding of the
factors impacting salt disproportionation during processing or storage as this can negatively impact
product quality and performance. To date, there is an incomplete understanding of key excipient
properties influencing salt disproportionation. Specifically, the potential roles of excipient
mobility and hygroscopicity, if any, on salt disproportionation are still not well understood.
Furthermore, the relationship between the compression and the extent of salt disproportionation is
an unknown factor. Herein, by utilizing various grades of polyvinylpyrolidone (PVP), its
copolymer, copovidone (PVPVA), and magnesium stearate, a systematic investigation on
disproportionation was performed using pioglitazone HCl as a model salt of a weak base. It was
observed that there was a poor correlation between excipient hygroscopicity and the rate and extent
of disproportionation. However, powder compression into compacts enhanced the rate and extent
of disproportionation. This work focused on disproportionation of the salt of a weak base, as basic
drugs are more prevalent, however, salts of weak acids may have similar tendencies under relevant
conditions. The knowledge gained from this study will help in understanding the role of various
excipients with respect to salt disproportionation, paving the way for designing stable salt
formulations.
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4.2

Introduction

Excipients, vital for the successful design of pharmaceutical formulations, present a wide range of
structural diversity. They can be either amorphous in nature, for example polymers such as
polyvinylpyrolidone (PVP) and croscarmellose sodium (CCS), or they can be present as crystalline
forms such as mannitol, lactose, and magnesium stearate [1-3]. Major considerations for excipient
selection include stability and interaction with the active pharmaceutical ingredient (API) [4, 5].
For instance, amorphous excipients can be hygroscopic, increasing the water content of the
formulation, and leading to undesirable effects for moisture sensitive APIs which can degrade or
react with excipients in the presence of water [6]. Crystalline excipients tend to be less
hygroscopic, but their partial amorphization during manufacturing can lead to variability in
product performance [7, 8].

Acidic or basic excipients, when combined with the salt form of an API, can lead to ion-exchange
reactions, known as salt disproportionation [9]. Salt disproportionation, a type of acid-base
reaction, is the conversion of the salt form of an API to its free form [10]. These reactions can be
considered as the reverse process of salt formation. For instance, during salt formation, the free
base is reacted with an acid to form the salt, while, in the case of disproportionation, the salt of a
weak base, when comes in contact with a basic microenvironmental pH (as induced by a basic
excipient), forms the free base [11]. In short, for the salt of a weak base, disproportionation
involves the transfer of a proton from the drug to the excipient. Due to the ubiquitous nature of
water, and its ability to act as a medium for proton transfer and salt disproportionation, water is
expected to play a role in disproportionation [12].
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Salt disproportionation results in formation of the unionized form of the API which is typically
orders of magnitude less soluble than the corresponding ionic form [10]. This may decrease API
bioavailability, with a negative impact for the patient [9, 10]. Several instances of salt
disproportionation have been reported, for example, miconazole mesylate and pioglitazone
hydrochloride convert to free base in presence of CCS and magnesium stearate (MS) [12-14]. In
addition, partial disproportionation of prasugrel HCl during processing decreased bioavailability
in patients with elevated gastric pH, as a result of the conversion to free base and the resultant
decrease in solubility [15]. There have been some attempts to deconvolute the various factors that
govern salt disproportionation reactions. Although it has been established that certain
physicochemical properties of excipients including particle size and basicity play a major role, [11,
12]. much of the work to date has focused on the link between disproportionation tendency and
API properties. Thus factors such as excipient mobility, water content and/or water activity have
not received attention.

The objective of this study was to understand the influence of excipient hygroscopicity and
mobility on the salt disproportionation reaction occurring between the salt of a weakly basic drug
and a basic excipient. Pioglitazone HCl (PIOH) was used as the model salt and MS was the basic
agent; this system was previously shown to undergo disproportionation [13, 14, 16]. Various
grades of PVP and its copolymer, poly(1-vinylpyrrolidone-co-vinyl acetate) (PVPVA), were used
to investigate the impact of water content and excipient glass transition temperature (Tg). Raman
spectroscopy was used to monitor the progress of disproportionation. First, to determine the effect
of the excipient mobility on salt disproportionation, PVPK12 and PVPK90 were used. These
polymers have similar water content when stored at a given RH, but varying mobility (based on
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Tg), allowing the importance of excipient mobility on salt disproportionation to be evaluated.
Second, to probe the impact of excipient hygroscopicity on salt disproportionation, PVP and
PVPVA were used. These polymers have similar mobility (based on Tg), but varying water
content, allowing evaluation of the effect of water content on salt disproportionation. Control
samples without hygroscopic excipients were also evaluated.

4.3

Experimental section

4.3.1 Materials
PIOH was obtained from the Tokyo Chemical Industry Co, Ltd. (Portland, OR). PVPK12,
PVPK90, and PVPVA was generously provided by BASF (Florham Park, NJ). MS was supplied
by Brand Nu Labs (Meriden, CT). Fumed silica (Aerosil® R 972, hydrophobic) and mannitol were
purchased from Evonik Corporation (Parsippany, NJ) and Sigma-Aldrich (Saint Louis, MO),
respectively. Sodium hydroxide (NaOH) and hydrochloric acid (HCl) were purchased from Fisher
Scientiﬁc (Pittsburgh, PA). All the chemicals were >99% of purity. The molecular structures of
PIOH and the excipients are shown in Figure. 4.1. Pioglitazone (PIO) free base was obtained by
slurrying an excess amount of PIOH in 1 M NaOH solution at 700 rpm for 3 hr. The resultant
solids were then vacuum filtered, washed with water, and air dried.
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Figure 4.1 Chemical structures of PIOH, MS, PVP, PVPVA, hydrophobic fumed silica, and
mannitol.
4.3.2 Methods
4.3.2.1 X-ray powder diffraction (XRPD)
A Rigaku SmartLab (XRD 6000) diﬀractometer (The Woodlands, TX) was used to collect
diffraction patterns with Bragg−Brentano mode using CuKα radiation (λ = 0.15405 nm) as
described previously [17]. About 40 mg of sample was placed onto a sample holder and the
diffraction data were recorded (at room temperature) with a step size of 0.02° between 5° to 40°
2θ.
4.3.2.2 Attenuated Total Reflectance Fourier Transform Infrared Spectroscopy (ATR-FTIR)
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A Bruker Vertex 70 spectrometer (Bruker Co., Billerica, MA) was used to generate ATR-FTIR
spectra as described previously [18, 19]. The instrument is equipped with a Golden Gate attenuated
total reflectance (ATR) sampling accessory with a diamond crystal (Specac Ltd., Orpington, UK).
Data collection and analysis were performed using the OPUS software (Bruker Co., Billerica, MA).
A small quantity of sample was placed on to the diamond crystal of the ATR accessory and the
FTIR spectra were generated at a resolution of 4 cm−1 by accumulating 64 scans between 650 cm−1
and 3950 cm−1.
4.3.2.3 Differential Scanning Calorimetry (DSC)
A Q2000 DSC (TA instruments, New Castle, DE) was used to generate the thermal profiles of
various samples as described previously [20]. A refrigerated cooling accessory (RCS) (TA
instruments, New Castle, DE) was used to cool the furnace and the instrument was purged with
nitrogen gas continuously. A Tzero pan with a hermetic Tzero lid (TA instruments, New Castle,
DE) was used and about 10 mg of each sample was heated using a heating rate of 10 °C/min. The
TA Analysis software (TA instruments, New Castle, DE) was used to determine the midpoint Tg
and the onset of melting temperature.
4.3.2.4 Thermogravimetric analysis (TGA)
A Q500 TGA (TA instruments, New Castle, DE) was used to generate the thermogravimetric
profile of PIOH as described previously [21]. The instrument was purged with nitrogen gas
continuously. A platinum pan (TA instruments, New Castle, DE) was used and the sample was
heated to 500 °C with a heating rate of 10 °C/min. The TA Analysis software (TA instruments,
New Castle, DE) was used for data analysis.
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4.3.2.5 pH-solubility profile
The pH-solubility profile of PIO was obtained using the slurry method. An excess amount of PIO
was allowed to slurry for 48 hr in water with varying pH values ranging from 0.5 to 8 (adjusted
using HCl). An Optima L-100 XP ultracentrifuge (Beckman Coulter, Inc., Brea, CA) was used to
remove the excess solids (35,000 rpm for 30 min). An Agilent 1290 Infinity Series high
performance liquid chromatography (HPLC) system (Agilent Technologies, Santa Clara, CA) was
then used to determine the concentration in the supernatant. An Inertsil® ODS-3 C18 5 μm, 4.6 ×
100 mm column (GL Sciences Inc., Rolling Hills Estates, CA) was used. Mobile phase with a flow
rate of 1 mL/min consisted of a mixture of 0.1% trifluroacetic acid in water (70%) and acetonitrile
(30%). An injection volume of 30 μL was used for all samples. The elution of the PIO was
monitored at 210 nm using an ultraviolet detector. A calibration curve (R2 value of 0.997) was
used to determine the concentration of each sample. Dilution of the samples with the mobile phase
was performed if necessary during the analysis.
4.3.2.6 pKa determination
A Sirius inForm instrument (Sirius Analytical, Forest Row, U.K.) was used to experimentally
determine the pKa of PIO. An acid−base titration method coupled with UV spectroscopy was used
as described previously [22]. Briefly, a stock solution of PIO was prepared in 1 M HCl. A solution
of 0.15 M NaCl in water was used as a titration medium along with 0.5 M HCl (acid) and 0.5 M
NaOH (base) as titrant. The sample and solutions were placed in the sample holder of the Sirius
inForm, from where the medium and the sample can be automatically dispensed and titrated with
acid and base. The experiment was performed at 37 °C and UV spectra were collected
simultaneously during the titration. The pKa was determined from any changes in the UV
absorbance spectra as a function of pH by the Refine software (Sirius Analytical, Forest Row,
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U.K.). In addition, pKa was also determined by fitting the solubility data to the
Henderson−Hasselbalch equation as follows: [23].
log S = log S0 + log (1 + 10pKa-pH)

(1)

Where, the pKa is related to the acid dissociation constant (Ka) of the protonated drug, S0 is the
intrinsic solubility of the free base, and S is the solubility at a given pH.
4.3.2.7 Moisture sorption analysis
A symmetrical gravimetric analyzer (SGA-100; VTI Corporation, Hialeah, FL) was used to
measure the water uptake of various samples. First, the samples were dried at 25 °C by purging
the dry nitrogen gas into the moisture sorption instrument. The samples were allowed to dry with
an equilibrium criterion of <0.01% w/w change within 2 min and a maximum drying time of 60
min. The sample was then exposed to either 75% or 57% RH, 40 °C. The sample was allowed to
attain equilibrium for a maximum of 180 min. The percent water uptake for the samples of MS +
PIOH and Mannitol + MS + PIOH were obtained following storage in a stability chamber at 75%
RH and 40 °C for 14 days, as these samples did not achieve equilibrium within 180 min.
4.3.2.8 Sample preparation for disproportionation study
Before preparing the sample mixtures, PIOH, PVPK12, PVPK90, and PVPVA were individually
stored in desiccators over calcium sulfate (W. A. Hammond Drierite Co. Ltd., Xenia, OH) for a
week at 25 °C to remove any residual moisture. Each polymer, MS, and PIOH were used to
produce ternary mixtures at a weight ratio of 6:1:3, which represents a typical formulation as used
previously in a similar study [24]. In the case of fumed silica, because of very low bulk density
(0.06 g/cm3), the ratio of silica + MS + PIOH was kept at 2:1:3. Samples were prepared by
geometrically mixing the polymer with MS, followed by geometric mixing with PIOH using a
spatula. All the samples were prepared in a controlled environment of ~20 % RH. Each sample
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was prepared in triplicate. Samples were then exposed to 75 % RH at 40 °C. In addition, control
samples of PIOH alone, polymers + PIOH, and MS + PIOH mixtures were also prepared and stored
under similar conditions. To monitor the progress of salt disproportionation, Raman spectra were
periodically acquired.
4.3.2.9 Raman spectroscopy
A RamanRxn2 Analyzer (Kaiser Optical Systems, Inc., Ann Arbor, MI) equipped with a PhAT
probe, was used to collect Raman spectra of the samples. A Raman laser source with 785 nm high
power NIR diode laser (Invictus) was used. A PhAT probe with a 6 mm laser spot size was used
and back scattered radiation was delivered to the base unit through the fiber bundle. A specially
designed sample holder with a controlled thickness was used to obtain reproducible results.
Instrument calibration was performed with ASTM standards namely cyclohexane, neon atomic
lines, and white-light source for calibrating the laser excitation wavelength, spectrograph
wavelength, and instrument spectral response, respectively. First, the CCD was cooled to −40 °C,
and then a dark subtraction was automatically applied to each spectrum. To obtain the Raman
spectrum of a sample, 6 scans were accumulated at an exposure time of 10 s each (400 mW). To
analyze the data, Grams AI (Thermo, Inc. Waltham, MA) was used.
4.3.2.10 Polarized light microscopy (PLM)
An Eclipse E600 POL microscope equipped with a DS Fi1 camera (Nikon Corporation, Tokyo,
Japan) was used to obtain images under cross-polarized light in transmittance mode. Briefly, a few
particles of the samples were placed onto a clean microscope slide and mounted onto the stage.
The images were then obtained and the size of 100 particles was measured using Image J software
(Version 1.8, developed by the National Institutes of Health).
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4.3.2.11 Tablet preparation
The powder blend was added to a stainless steel die with a diameter of 10 mm. The tablets were
then prepared by compressing the powder blend using a Specac IR press (Grasby Specac, Kent,
UK) with applied pressure of 700 psi and a dwell time of 10 sec.

4.4

Results

4.4.1 XRPD analysis of PIO free base and PIOH
PIOH was slurried in 0.1 N NaOH to obtain the PIO free base. The XRPD patterns of the obtained
free base matches the reference powder pattern, [25]. indicating successful preparation of PIO free
base (Figure S1). To check the polymorphic form and purity of PIOH, XRPD and FTIR were
performed. The X-ray diffraction patterns (Figure 4.2 and S2) and FTIR spectra (Figure S3)
indicated that the reference material is the phase pure Form I polymorph of PIOH which contains
no detectable free base.

Figure 4.2 XRPD patterns of (A) PIOH and (B) PIO free base.
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4.4.2 Thermal analysis of PIOH
The DSC traces of PIOH showed a sharp endotherm with an onset temperature of ~200 °C
followed by a broad peak spanning from 250 to 350 °C (Figure 4.3). TGA data showed that PIOH
loses weight gradually beyond the melting point, indicating loss of HCl and/or degradation (Figure
4.3). These results suggest that the salt is stable up to its melting point.

Figure 4.3 Overlay of (A) DSC patterns and (B) TGA pattern of PIOH.

4.4.3 pHmax and pKa determination
Previous research indicates that the pHmax is a critical factor which governs the rate and extent of
disproportionation [12, 26]. To evaluate this parameter, the pH-solubility profile of PIO was
determined. The data (Figure 4.4) show that the solubility is constant from pH 8 to 6, and then
increases exponentially as the pH is further lowered. The solubility reached a plateau at pH 1.
XRPD analysis demonstrated that the solid form obtained after slurrying at pH 8 to 2 was the free
base, at pH 1.5 to 1 it consisted of a mixture of PIOH and PIO free base, while at pH 0.5, the pure
HCl salt form was obtained (Table S1). Based on these data, pHmax was determined to be 0.8
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(Figure 4.4). The pKa as determined using UV spectroscopy was found to be 5.6 ± 0.2, which is
consistent with the previously reported value [16].

Figure 4.4 Experimental pH-solubility profile of the PIO showing pHmax.

4.4.4 Particle size distribution analysis
It is known that particle size can influence the rate and extent of disproportionation [11]. Therefore,
the particle size of PIOH and various excipients were determined. The particle size distribution
analysis indicated that, except for fumed silica, PIOH and the other excipients have a similar size
distribution profile (Figure S4 and S5). The fumed silica has narrow particle size distribution, with
about 70% of particles falling in the 20-60 µm range (Figure S5).
4.4.5 Determination of Tg and water content of various polymeric excipients
DSC was used to determine the Tg of the polymeric excipients used in this study. The Tgs of PVP
K12, PVP K90, and PVP VA were found to be -12.1 ± 0.4, 32.0 ± 0.9, and 26 ± 1°C, respectively,
when stored at 40 °C and 75 % RH (Figure 4.5). The amount of water taken up by different
excipients or the mixtures was also determined. PVP K12, PVP K90, and PVP VA had % weight
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gains of 30.1 ± 0.6, 31.5 ± 0.2, and 17.3 ± 0.1, respectively, when stored at 40 °C and 75 % RH.
These observations indicate that, under these storage conditions, PVP K12 and PVP K90 have
similar water contents but different Tgs, while PVP K90 and PVP VA have similar Tgs but
different water contents.

Figure 4.5 DSC pattern of (a) PVP K12, (b) PVP K90, and (c) PVP VA.

4.4.6 Standard calibration curves
Raman spectroscopy has been used previously to quantify disproportionation [27]. To identify
distinct peaks for quantification, Raman spectra of the blends of PIOH and PIO free base with
various excipients were collected. The Raman spectra of PIO free base, PIOH, PVP K12, PVP
K90, PVP VA, mannitol, and fumed silica are shown in Figure 4.6. There are two strong and
distinct API peaks visible at 1609 cm-1 (Peak I) and 1638 cm-1 (Peak II). None of the excipients
showed spectral interference in this region. This spectral region also enable differentiation of PIOH
from PIO free base, as the former has both Peaks I and II, while the free base has only Peak I.
Using these peaks, a calibration curve was prepared to enable quantification of the extent of
disproportionation.
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Figure 4.6 Raman spectra of (a) Mannitol, (b) Fumed Silica, (c) MS, (d) PVPVA, (e) PVPK90,
(f) PVPK12, (g) PIOH, and (h) PIO free base. Dotted line indicates the characteristic peak I
and peak II of PIOH.

By mixing known weight percentages of PIOH and PIO free base ranging from 10% PIOH (90%
PIO free base) to 100% PIOH (0% PIO free base), various calibration samples were prepared as
described previously [24]. The calibration samples were prepared in triplicate by geometrical
mixing and analyzed immediately by Raman spectroscopy. A calibration curve was prepared by
plotting the intensity ratios of Peak I and II for various weight percentage of PIOH salt in the
mixtures (Figure S6). Another set of samples was prepared in triplicate having similar weight
percent of PIOH and PIO free base, to validate the calibration curve. The data shows that the
validation points are consistent with the calibration points (Figure S6). Furthermore, a low value
(2%) of the root mean square error of prediction (RMSEP) and a high value of R2 (0.99) for the
calibration curve, indicates that PIOH disproportionation can be readily quantified using this
approach.
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4.4.7 Disproportionation of PIOH blended with different excipients
To assess the impact of different excipient properties on the disproportionation of the PIOH salt,
a ternary blend was prepared by mixing a diluent (PVP K12/PVP K90/PVP VA/fumed
silica/mannitol) with the basic excipient, MS, followed by mixing of this blend with PIOH. These
blends were stored at accelerated stability conditions (40 °C and 75 % RH). Raman spectroscopy
was used to determine the extent disproportionation as a function of time. Ternary blends with
PVP K12 showed the highest rate and extent of disproportionation followed by PVP VA and PVP
K90 ternary blends (Figure 4.7). To evaluate the impact of water activity (rather than water
content) on disproportionation, samples of PVP K12 with MS and PIOH were also stored at 40 °C
and 57 % RH. The rate and the extent of disproportionation for this mixture was similar to that
observed for PVP VA with MS and PIOH stored at 40 °C and 75 % RH (Figure 4.7); these two
samples have similar water contents. The control samples containing polymer and PIOH (without
MS) showed minimal, but not zero disproportionation (Figure 4.7).

Figure 4.7 Salt disproportionation of PIOH as a function of time at 40 °C and 75 % RH with
and without different polymeric excipients. The values in the parentheses stands for the ratio
of each ingredients used in the mixture.
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To determine if the order of ingredient mixing influences disproportionation, an additional sample
of PVP K12 with MS and PIOH was prepared where the polymer was first mixed with PIOH,
followed by blending MS. The rate and extent of PIOH disproportionation were similar to those
seen for the sample prepared by first mixing the PVP K12 and MS, followed by mixing with PIOH
(Figure 4.7 and 4.8). In addition, mixtures of MS and PIOH at ratios of 1:3 and 1:9 were also
analyzed. As shown in Figure 4.8, MS + PIOH at a 1:3 ratio showed a higher rate and extent of
disproportionation as compared to the 1:9 ratio.

To further understand how neutral and potentially non-reactive excipients could influence
disproportionation, blends of mannitol or fumed silica with MS and PIOH were also evaluated.
The rate and extent of disproportionation for the mannitol blends were similar to those of the MS
+ PIOH (1:3) blend, while the disproportionation of the fumed silica blend was found to be closer
to that of the MS + PIOH (1:9) blend. Control samples containing PIOH with mannitol or fumed
silica (without MS) showed negligible disproportionation.

To confirm the formation of the crystalline PIO free base following disproportionation, XRPD
analysis was also conducted. Samples containing MS showed reflections corresponding to PIO
free base (Figure S7A and B). However, PIOH alone showed no changes in diffraction pattern
after exposure to 40 °C and 75 % RH for 12 days, indicating that PIOH does not undergo any
phase transformations (Figure S7C). The formation of stearic acid as the second reaction product
was confirmed using FTIR spectroscopy.
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Figure 4.8 Salt disproportionation of PIOH as a function of time at 40 °C and 75 % RH with
and without different control excipients. The values in the parentheses stands for the ratio of
each ingredients used in the mixture.

The amounts of water acquired by the various samples evaluated in the disproportionation studies
are presented in Table S2. No specific correlations between sample water content and the extent
of disproportionation could be observed as summarized in Figure 4.9. However, the data clearly
show that the extent of disproportionation for samples containing MS is higher than for sample
without MS, irrespective of their water content.
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Figure 4.9 Bar graph showing % disproportionation at 40 °C and 75 % RH for various samples
with increasing % water uptake. a These values of water uptake were obtained by exposing the
sample in a stability chamber maintained at 75% RH and 40 °C for 14 days, other water
contents were obtained by equilibration of the fresh blend with water vapor at 75% RH at
40 °C.

To further evaluate the effect of Tg on the extent of disproportionation, the data were compared
for samples containing polymers with different Tgs. It is apparent that the extent of the
disproportionation decreases as polymer Tg increases at the given storage condition (Figure
4.10A). A similar comparison for samples with a different water activity but with similar water
content was also performed, but no noticeable differences were observed (Figure 4.10B).
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Figure 4.10 Bar graph showing % disproportionation at 40 °C and 75 % RH for various
samples. (A) Samples with different Tg and (B) samples with different water activity (Wa).

To probe the impact of temperature, selected blends were evaluated at a storage temperature of
25°C, which is above the Tg of PVP K12 and below the Tg of PVP K90 at 75% RH. At the storage
condition of 25°C and 75% RH, the rate and extent of disproportionation for PVP K12 blends are
higher than for PVP K90 blends (Figure 4.11A).

To evaluate the effect of compression on salt disproportionation, mannitol was used as a diluent,
as it is less hygroscopic and neutral material. The results showed a dramatic increase in the rate
and extent of disproportionation when the material is compressed in the form of tablet as compared
to the powder blend (Figure 4.11B and S9). In general, the rate of disproportionation was much
slower at 25 °C as compared to 40 °C.
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Figure 4.11 Salt disproportionation of PIOH as a function of time at 25 °C and 75 % RH. (A)
with PVP K12 and PVP K90 in the form of powder blend, and (B) with mannitol in the form
of powder blend and tablet. The value in the parentheses stands for the ratio of each ingredient
used in the mixture.

4.5

Discussion

Disproportionation is a major concern for formulations containing a salt form of a basic API with
low a pHmax in oral solid dosage forms. Several studies have attempted to deconvolute factors
determining the extent of salt disproportionation. Merritt et al., developed a mechanistic model to
predict the extent of disproportionation for various salts. They noted trends in the extent of
disproportionation with relative humidity, formulation excipients, base pKa and solubility of the
free base API and its salt [28]. John et al. pointed out the importance of the proton accepting
capacity of the disproportionating agent [13]. The impact of particle size, pHmax, temperature,
relative humidity, and solid form on the salt disproportionation were also studied previously [11,
21, 29].

The Merritt approach, which describes the disproportionation reaction in solid state formulations,
is based on a model that invokes a surface moisture layer on solid particles whereby the acid-base
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reaction occurs in a saturated solution created by solvation/mobilization of reactive species; this
type of approach has been widely used to model chemical reactions [30-32]. Consequently, to
apply this model, there is a need to estimate the available volume of water, which in turn is used
to calculate the amount of dissolved species. This estimate is typically based on the weighted sum
of the moisture sorption profiles of the API and excipients. There are at least two assumptions
inherent to this approach that needs to be considered. First, that all of the water present in the
formulation, as measured by the water sorption experiments is available to generate the solution
environment where the solids dissolve to saturation and the acid base reaction occurs. Second, that
water diffusion is sufficiently fast relative to the progress of the solid state reaction, such that the
pH of the water layer is at equilibrium.

While the Merritt model has considerably advanced understanding of the multifaceted interplay of
factors impacting disproportionation, the role of water content per se appears to be more complex
than as described in the existing model. For example, for basic additives capable of forming
hydrates, considerable discrepancy was seen between model predictions using the total amount of
water present in the powder blends as estimated from water sorption isotherms, and the
experimental results [29]. The discrepancy was rationalized by considering that water present in a
crystal lattice cannot contribute to the solvation of acidic and basic species. The results of the
current study provide further insight into the role of water, both water content and water activity,
as well as excipient mobility, in impacting the disproportionation reaction.

Based on current understanding, it might be anticipated that adding a neutral, but highly
hygroscopic excipient to a formulation containing the salt of a weak base and a basic excipient,
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would lead to an increase in the extent of disproportionation, as a result of the increase in the
overall water content. Figure 4.9 shows that this is clearly not the case. The MS + PIOH 1:3 ratio
blend can be considered as the control system against which comparisons can be made. First, we
can consider the impact of adding an “inert” low hygroscopicity crystalline excipient, mannitol.
Here, it is apparent that dilution of the system by mannitol particles does not impact the extent of
the acid base reaction within experimental error. Next, we can compare the impact of the highly
hygroscopic PVP polymers. The presence of either K90 or K12 leads to a blend with a fourfold
increase in the water content relative to the reference blend (MS + PIOH 1:3), however, for the
K90 system the extent of disproportionation decreases, while for the K12 polymer, the extent of
the reaction increases by about 5% (statistically significant as per student’s t test, p<0.05). It is
possible that this difference arises due to the different glass transition temperatures of the two PVP
grades, although at this temperature and water content, both polymers are above Tg. However,
K12 is much farther above Tg as compared to K90, more than 50 versus less than 10°C. This in
turn may impact that diffusivity of water molecules and/or protons through the polymer matrix.
Having said this, it is clear that the water associated with the polymer does not contribute to a
proportional increase in disproportionation extent, as would be predicted using current models.
We also do not see a discriminatory effect when we vary water activity and keep the water content
to a similar value; a comparison of the PVP K12 system stored at 57% RH and with the blend
containing the less hygroscopic copolymer, PVPVA at 75% RH, shows a similar extent of
disproportionation.

Rather than water content per se being the main driver of disproportionation, 4 other factors were
observed to have a much greater impact. These were 1) the amount of the basic excipient added,
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2) temperature, 3) powder versus compact and 4) the presence of fumed silica. The first
observation is straightforward to rationalize. Increasing the amount of MS from a 1:9 to a 1:3
relative ratio increased the extent of disproportionation by a factor of more than 2. This increase
in disproportionation corresponds to increase in the molar ratio of the basic excipient to that of the
salt. Taking into consideration the molecular weight of MS (591.3 g/mol) and PIOH (392.9 g/mol),
for a blend of 100 mg, increasing the amount of MS from a 1:9 to a 1:3, increases the MS mole
fraction from 0.07 (0.017 mM of MS and 0.229 mM of PIOH) to 0.22 (0.042 mM of MS and 0.191
mM of PIOH).

Temperature clearly has a dramatic impact on both the kinetics and extent of disproportionation,
which is consistent with temperature effects discussed previously [11]. The disproportionation data
for experiment performed at 25 °C and 75 % RH indicated that rate and extent of
disproportionation is lower than for the corresponding system at 40 °C and 75 % RH. This could
be due to a lower mobility at lower temperature, as well a reduced solubility in the surface moisture
layer. In addition, this experiment evaluated the impact of excipient mobility on
disproportionation; at 25 °C the experimental temperature is above the Tg of the PVP K12 (~-12
°C), but below the Tg of the PVP K90 (~31 °C). The results suggest that the disproportionation is
faster when the excipient is above Tg, compared to when in the glassy state.

Disproportionation also occurs much more rapidly in tablets as compared to in the powder blends.
Analyzing the disproportionation of PIOH in tablets versus a blend containing mannitol + MS +
PIOH (6:1:3) at 25 °C and 75 % RH, it can be noted that salt-to-free base conversion occurs more
rapidly in tablets as compared to in the powder blend, which is presumably due to higher number
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of direct contacts between the salt and the basic excipients in the compact resulting from the
tableting process. In addition, local amorphization may occur due to the compression process,
which could result in greater mobility and higher water content.

The notable impact of fumed silica on the extent of disproportionation deserves more comment.
The effect is most likely attributable to two factors. First, silica is known to adhere to particulate
surfaces, forming a microcoating [33]. This may reduce contact between PIOH and MS, decreasing
the extent of the reaction, by acting as a barrier. Second, due to the presence of surface silanol
groups, silica has been reported to have an acidic surface (pH 3.6-5.5) [34]. This may act to alter
the microenvironmental pH, reducing the extent of disproportionation. Previous studies have
demonstrated that adding acidic excipients can reduce the tendency for salt disproportionation
[35].

4.6

Conclusions

It is crucial to understand the various factors affecting salt disproportionation in order to design a
robust formulation. In this study, by utilizing PIOH as a model salt, we have demonstrated that,
somewhat counterintuitively, adding neutral but hygroscopic excipients to a formulation of PIOH
and a basic excipient does not necessarily increase the extent of disproportionation. In other words,
a poor correlation is observed between the total moisture content of the formulation and the extent
of salt to free base conversion. Instead, the most important factors impacting the extent of
conversion are the amount of the basic excipient present relative to the salt, temperature and the
degree of contact between the components in the powder. Thus compression of the powder blend
led to an increased rate of salt disproportionation. Understanding the role of various excipient,
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storage conditions and sample compression with respect to salt disproportionation, it therefore
necessary in order to produce stable salt formulations.

4.7
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4.8

Supporting information

4.8.1 Supporting figures

Figure S1. Comparison of XRPD patterns of PIO free base as presented in previous literature,
[1]. (top) and obtained by slurry method in this study (bottom).

Figure S2. Comparison of XRPD patterns of experimental PIOH (top) and calculated Form I of
PIOH – Ref code - FAYDUF (bottom).
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Figure S3. FTIR spectra of (a) PIOH and (b) PIO free base.

Figure S4. Polarized light microscopic images of PIOH, PVP K12, PVP K90, PVP VA.
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Figure S5. Particle size distribution for PIOH, PVP K12, PVP K90, PVP VA.

Figure S6. Calibration curve obtained by plotting peak intensity ration of Peak II/Peak I against
the % PIOH salt in the mixture. R2 and RMSEP are also shown.
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Figure S7. XRPD patterns of various sample obtained after exposure to 40 °C and 75 %
RH for 12 days. (A) (a) PVP K12 + MS + PIOH (6:1:3), (b) PVP K90 + MS + PIOH (6:1:3),
(c) PVP VA + MS + PIOH (6:1:3), (d) PVP K12 + MS + PIOH (57%RH) (6:1:3), (e) PVP K12 +
PIOH (6:3), (f) PVP K90 + PIOH (6:3), and (g) PVP VA + PIOH (6:3). (B) (a) Mannitol + PIOH
(6:3), (b) Mannitol + MS + PIOH (6:1:3), (c) Fumed Silica + PIOH (2:3), (d) Fumed Silica + MS
+ PIOH (2:1:3), (e) PVP K12 + PIOH + MS (6:3:1), (f) MS + PIOH (1:3), and (g) MS + PIOH
(1:9). (C) PIOH. Vertical dotted line indicates peak corresponds to crystalline PIO free base.
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Figure S8. FTIR spectra of (a) MS, (b) MS + HCl, (c) MS + PIOH (1:3), (d) MS + PIOH (1:9),
(e) PVP VA + MS + PIOH (6:1:3), (f) PVP K90 + MS + PIOH (6:1:3), (g) PVP K12 + MS +
PIOH (6:1:3), (h) Mannitol + MS + PIOH (6:1:3), (i) Fumed Silica + MS + PIOH (2:1:3), (j)
PIOH, (k) PVP VA, (l) PVP K90, (m) PVP K12. Vertical dashed line indicates the stearic acid
peak.
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Figure S9. Salt disproportionation of PIOH as a function of time at 40 °C and 75 % RH for tablet
containing mannitol, MS, and PIOH (6:1:3)). The values in the bracket stands for the ratio of
each ingredients used in the mixture.
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4.8.2 Supporting tables
Table S1. Solid form obtained after slurrying PIO free base at various pH for 48 hr.
pH
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
6.5
7
8

Solid form
Salt
Mixture
Mixture
Free base
Free base
Free base
Free base
Free base
Free base
Free base
Free base
Free base
Free base
Free base
Free base

146
Table S2. Percent water update for various samples when exposed to 40 °C and 75 % RH.
Sample
Fumed Silica + PIOH (2:3)
Mannitol + PIOH (6:3)
Fumed Silica + MS + PIOH (2:1:3)
Mannitol + MS + PIOH (6:1:3)
PIOH
MS + PIOH (1:9)

% Water uptake (w/w)
0.55 ± 0.22
0.68 ± 0.12
0.78 ± 0.15
3.08 ± 0.49
0.87 ± 0.25
3.06 ± 0.24

MS + PIOH (1:3)

5.75 ± 0.41

PVP VA + MS + PIOH (6:1:3)

11.98 ± 0.39

PVP VA + PIOH (6:3)

12.64 ± 0.15

PVP K12 + MS + PIOH (57%RH) (6:1:3)

12.71 ± 0.32

PVP K90 + MS + PIOH (6:1:3)

19.46 ± 0.39

PVP K12 + PIOH (6:3)

20.87 ± 0.35

PVP K12 + MS + PIOH (6:1:3)

21.05 ± 0.63

PVP K12 + PIOH + MS (6:3:1)

22.38 ± 0.23

PVP K90 + PIOH (6:3)

22.65 ± 0.26

PVP K12
PVP K90
PVP VA
Fumed Silica
Mannitol
MS
PVP K12 + MS + PIOH (6:1:3)*
PVP K90 + MS + PIOH (6:1:3)*
Mannitol + MS + PIOH (6:1:3)*
*samples were analyzed at 25 °C and 75 % RH

30.14 ± 0.58
31.54 ± 0.21
17.35 ± 0.08
0.24 ± 0.09
0.29 ± 0.19
0.91 ± 0.03
23.56 ± 1.98
21.03 ± 1.07
0.42 ± 0.16
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